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ABSTRACT
 Upon returning from the first Gulf War, soldiers cited a plethora of unexplained 
physical and cognitive deficits which have since been termed Gulf War Illness (GWI). 
Presentation of GWI is positively correlated with pyridostigmine bromide (PB) use, 
which was prophylactically administered to soldiers in response to threats of chemical 
warfare. To test the overarching hypothesis that PB interacted with stress of 
deployment to alter neural, endocrine, and immune systems, the following studies used 
a 2×2 rodent model with 14 days of drug treatment (vehicle; PB) and 10 days of 
repeated restraint stress (stressed) or non-stressed-control conditions. Results indicate 
that PB decreases cholinesterase activity acutely but sensitizes it by three months post-
treatment selectively in rats also subjected to stress. Similarly, only rats in the PB-
stressed condition exhibit elevations in corticosterone three months post-treatment. 
These results suggest that PB and stress interact to progressively disrupt homeostasis in 
peripheral measures. To test whether PB and stress also interact to influence central 
neurotransmitter function, an in vivo microdialysis study was performed in a separate 
GWI cohort where rats were subjected to an immune challenge (30 µg/kg 
lipopolysaccharide; LPS) followed 48 hours later by an acute restraint stress challenge. 
Acetylcholine and glutamate levels were assessed in both the prefrontal cortex (PFC) 
and hippocampus. Results indicate that a history of restraint stress attenuates the 
cholinergic and glutamatergic responses to both LPS and restraint stress challenges. PB 
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in the absence of stress decreases the cholinergic response to restraint stress challenge 
in both the PFC and hippocampus. In contrast, PB in combination with a history of 
restraint stress interact to preferentially increase the glutamatergic response in the 
hippocampus. These results indicate that PB preferentially disrupts cholinergic systems 
whereas PB and stress interact synergistically to disrupt glutamatergic systems, 
providing insight into possible mechanisms underlying cognitive impairments observed 
in soldiers with GWI. 
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PREFACE
The 1990-1991 Gulf War was brief, but the repercussions of that encounter can 
still be seen today in the 42% of Gulf War soldiers deployed in active combat zones who 
now report chronic multi-symptom illness (L. Steele, 2000). Although the federal 
government originally denied any association with Gulf War deployment and ontogeny 
of symptomology, this stance was revised as collective reports from veterans emerged 
and were collectively presented to Congress in 1997 (Burton, 1997). The excerpt which 
follows is from Sergeant Chris Kornkven’s testimony on his experiences with GWI to the 
U.S. House Committee on Government Reform and Oversight (Burton, 1997). The 
symptoms reported by Sergeant Kornkven are consistent with those reported by other 
soldiers with GWI: 
“While still in the Gulf I began experiencing symptoms that continue to this day. I 
had difficulty remembering significant events that happened days earlier... my 
knees and shoulders were especially painful... and fatigue stayed with me 
constantly... I reported blinding headaches with only offers of aspirin. I reported 
memory loss... dismissed as stress. I reported skin problems... and was told ‘it’s 
not cancer yet... come back as needed.’ I reported intestinal problems... and 
rectal bleeding... dismissed and no follow- up. I reported joint pain... diagnosed 
as fibromyalgia... no treatment other than Motrin. I reported chest pains... and 
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racing heart beats... and was told it was due to an abnormal heart valve... which 
was hereditary.” 
 Since this Congressional presentation, the Department of Defense and Veterans 
Affairs have funded numerous epidemiological, clinical, and preclinical studies to 
determine the cause, pathology, and treatment strategies for GWI. In the decade since 
this initiative was launched, we have gained much insight into potential causal factors. 
However, the specific underlying mechanisms driving the continued progression of GWI 
or successful treatment regimens remain to be elucidated. The following studies aim to 
advance our understanding of the pathophysiology of GWI as a precursor to the 
development of more targeted and successful pharmacological interventions in this 
population. 
xii 
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CHAPTER 1 
A HISTORY OF GULF WAR ILLNESS
On August 2, 1990, the United States along with a coalition of 35 nations invaded 
Iraq in response to its annexation of Kuwait. In total, this conflict lasted only one 
hundred hours, and this swift victory was paralleled by the lowest incidence of combat 
deaths in any war in U.S. history. Originally hailed as a military success, the latent costs 
of this victory emerged as returning veterans began citing a plethora of unexplained and 
unprecedented medical symptoms. These varied symptoms have been clustered into 
three broad classifications: impaired cognition, confusion-ataxia, and arthro-myo-
neuropathy (Haley, Kurt, & Hom, 1997). Impaired cognition includes memory loss, 
attention deficits, and decreased working memory capacity; confusion-ataxia refers to 
spatial disorientation, confusion, and balance disturbances; arthro-myo-neuropathy 
refers to muscle weakness and fatigue. These symptoms are differentiable from post-
traumatic stress disorder (PTSD) and symptoms reported by veterans of other wars, 
suggesting that unknown factor(s) in the Gulf War caused the onset of these symptoms 
(Haley, Kurt, & Hom, 1997). Furthermore, these same symptoms are reported by 
veterans of the Gulf War from other countries at similar rates to U.S. soldiers, making 
GWI a global phenomenon (Ikin et al., 2004; Unwin et al., 1999). In response to 
emerging concerns, the Department of Defense and Veteran Affairs began to 
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commission researched aimed at establishing causal links to GWI (CDC, OPHS, DHHS, 
NIH, & ATSDR, 1999). 
While the official cause of GWI remains unknown, there have been several 
proposed causes that have emerged with varying validity over the last decade including 
exposure to depleted uranium (the poisonous and radioactive material used for 
munitions), multiple vaccinations (yellow fever, anthrax, botulinum toxoid, hepatitis B, 
tetanus, polio, cholera, etc.), nerve gas exposure (lethal aerosolized agents which alter 
cholinergic nerve signaling), pyridostigmine bromide (PB) anti-nerve gas treatment, 
pesticides (N, N-diethyl-m-toluamide, DEET; permethrin), stress, oil well fires, insects, 
and parasites (Enserink, 2001). The vast range of toxic exposures linked to troops in the 
Gulf War have led some to consider GWI a result of a “toxic soup” of chemicals 
(Enserink, 2001). While several of these factors may have differentially impacted and 
contributed to symptoms in various individuals, labeling GWI as a “toxic soup” does not 
untangle the web of causes, interactions, and ontogeny of symptoms in relation to 
treatment options for veterans. In response to this issue, research has begun to identify 
factors with the strongest links to symptomology in subsets of Gulf War populations 
with a central focus on factors which were unique to Gulf War deployment.    
 
1.1 PYRIDOSTIGMINE BROMIDE AND THE RESPONSE TO CHEMICAL WARFARE 
One of the factors unique to the Gulf War which gained much attention was the 
direct threat of the use of G-series nerve gas agents by Saddam Hussein. In a famous 
broadcast by Saddam Hussein on April 2, 1990, he said: “By God, spare us your evil. Pick 
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up your goods and leave. We do not need an atomic bomb. We have the dual chemical. 
Let them take note of this. We have the dual chemical. It exists in Iraq” (Comprehensive 
Report of the Special Advisor to the DCI on Iraq’s WMD With Addendums, 2004). The 
dual chemical refers to a method for storing precursors for chemical warfare agents 
which become activated upon firing with munitions. This use of a binary form in 
chemical warfare enabled stockpiling large quantities G-series agents such as Sarin and 
Soman and posed a serious threat to the safety of the coalition of soldiers preparing for 
an invasion.  
These G-series nerve gas agents, so-named due to their original synthesis by 
German scientists in World War II, are the most toxic chemical warfare agents known 
(Sidell & Borak, 1992). They produce toxicity by irreversibly inhibiting cholinesterase 
(ChE) enzymes: acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Of the 
two, AChE is the primary enzyme which metabolizes acetylcholine. Cholinesterases 
hydrolize the neurotransmitter acetylcholine, resulting in its rapid breakdown into 
acetate and choline. Tight enzymatic control of cholinergic function is critical for the 
central and peripheral nervous systems, and disruption of cholinergic transmission has 
profound consequences on functioning. 
In the central nervous system, cholinergic projections are particularly dense in 
the neocortex and hippocampus where they modulate excitation of local circuitry to 
influence attention, arousal, and learning and memory (Fadel, 2011). While moderate 
hyperstimulation of central cholinergic function can disrupt these cognitive functions, 
cholinergic toxicity induced by G-series agents results in seizures and convulsions 
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(Braitman & Sparenborg, 1989). Irreversible inhibition of cholinesterase in the periphery 
has even more detrimental results. Acetylcholine is the critical neurotransmitter at 
neuromuscular junctions, secretory glands, and smooth muscles. As such, peripheral 
cholinergic hyperstimulation following irreversible cholinesterase inhibition results in 
vomiting, paralysis and ultimately death by asphyxiation (Pope, Karanth, & Liu, 2005; 
Tokuda, Kikuchi, Takahashi, & Stein, Gerald, 2006). Collectively, these symptoms 
following cholinergic overload are termed a “cholinergic crisis.”  
Because G-series nerve gas agents are aerosolized and rapidly soluble through all 
tissues, including the blood-brain-barrier, the threat of the use of G-series agents was a 
primary concern for the U.S. government. In response, the U.S. government found hope 
in preclinical literature which suggested that prophylactic administration of PB was 
protective against death in the event of exposure to G-series chemicals when combined 
with post-exposure doses of atropine and oximes (Dirnhuber, French, Green, 
Leadbeater, & Stratton, 1979; Von Bredow, Adams, Groff, & Vlck, 1991). PB is a 
reversible cholinesterase (ChE) inhibitor which binds competitively to the same site on 
cholinesterase as Sarin and Soman, thus protecting a portion of cholinesterases from 
Sarin and Soman’s irreversible inhibition (Aquilonius & Hartvig, 1986). Because repeated 
administration of this dose of PB in primates did not result in any overt behavioral 
changes, it was concluded that PB could be safely administered chronically to all soldiers 
deployed in active combat-zones where nerve gas exposure was a potential threat 
(Keeler, Hurst, & Dunn, 1991; Philippens et al., 1998; Von Bredow et al., 1991). The 
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result was that an estimated quarter-million soldiers in high-risk combat zones were 
authorized to take PB on a daily basis (Golomb, 2008).  
This authorization of the use of a pharmacological agent in humans in the 
absence of clinical trials or informed consent regarding that use was an historic event. 
The decision was based off the consideration that conductance of human clinical trials 
on lethality is inherently unethical. Eleven days prior to Operation Desert Storm, 
following requests from the Department of Defense, the Food and Drug Administration 
(FDA) created an interim rule to approve the use of PB on soldiers as an “investigational 
new drug” which enabled the experimental administration of PB in potentially lethal 
military situations in the absence of informed consent (Aebersold, 2012). PB remains 
formally approved as a prophylactic treatment for chemical warfare agents under what 
is colloquially termed “The Animal Rule” which was passed by the FDA in 2002 (Snoy, 
2010). The Animal Rule states that if traditional human clinical efficacy studies are not 
feasible or ethical, a drug or biological product that targets lethal or severely toxic 
conditions may be approved for human use following sufficient animal testing and 
reasonable expectation that the drug should be both safe and effective in humans. PB 
was the first of nine drugs ever approved under this legislation (CDER Drug and Biologic 
Animal Rule Approvals, 2017). 
The use of PB in soldiers was not expected to cause any adverse effects. This 
assessment was partially based off the fact that its use had already been approved for 
the treatment of myasthenia gravis, an autoimmune disorder which results in 
neuromuscular weakness. In addition, the dose necessary for protection of soldiers (30 
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mg, administered orally every 8 hours) is 10× lower than the dose prescribed for 
myasthenia gravis. These facts, in addition to large bodies of animal studies suggesting 
its efficacy as a nerve-gas pre-treatment and low-likelihood of crossing the blood-brain 
barrier due to a quaternary ammonium group (Ray et al., 1991) led confidence to the 
fact that its use should not negatively impact soldiers. Despite this confidence, 
mounting epidemiological evidence suggested that out of all of the various exposures to 
soldiers during the Gulf War, PB has the most consistently reported to have a positive 
correlation with the development of GWI with some evidence even supporting a 
positive dose-response relationship (Golomb, 2008; L Steele, Sastre, Gerkovich, & Cook, 
2012).  
The mechanism by which PB may have caused some of these effects remains 
controversial. For example, PB was not anticipated to cause any cognitive side effects as 
it was thought that PB does not cross the blood-brain barrier due to the presence of a 
charged quaternary ammonium group (Ray et al., 1991). However, soldiers emerging 
from the Gulf War reported a plethora of cognitive symptoms such as deficits in 
attention, concentration, learning, visuospatial functioning, depression, anxiety, 
sensorimotor abilities, and working and long-term memory (Robert W. Haley et al., 
1997; Lange et al., 2001). These clinical observations left researchers to determine how 
a peripherally acting drug could cause such drastic central nervous system effects. One 
theory which has garnered much support at preclinical levels, is that PB interacted with 
stress to produce unexpected and chronic physiological changes, contributing to the 
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development of GWI symptomology in both central and peripheral systems (Nisenbaum, 
Barrett, Reyes, & Reeves, 2000; L Steele et al., 2012).  
 
1.2 ESTABLISHING A MODEL OF GULF WAR ILLNESS 
Rodents have long been used to model human physiology and in health and 
disease because of their similarities in drug metabolism, cellular structure, and 
organization of nervous, cardiovascular, and immune systems. They provide an 
advantage over epidemiological studies due to their ability to control confounding 
variables and establish causal relationships between different variables. Over the last 
few decades, several rodent models of GWI have emerged to support this theory of an 
interaction between stress and PB on cognitive abilities. For example, acutely, PB 
exaggerates the behavioral response to acoustic startle in rats (Servatius et al., 2000). 
More chronic studies have demonstrated similar interactions between stress and 
cholinesterase inhibitors. Five minutes of daily restraint stress over the course of four 
weeks exacerbates the adverse effects of a cocktail of PB, permethrin, and DEET on 
memory formation and retrieval in the Morris Water Maze (Parihar, Hattiangady, Shuai, 
& Shetty, 2013) as well as performance in novel object and novel place recognition tasks 
(Hattiangady et al., 2014). These studies suggest that PB and stress cause deficits in 
learning and working memory. While these exacerbated cognitive deficits by 
combinations of stress and PB are well-replicated across preclinical literature, what 
remains unclear is 1) the specific role of PB in these cholinesterase-stress interactions, 
and 2) the mechanism by which stress and PB interact to induce these deficits. 
8 
Therefore, the current study used a model of repeated administration of PB by gavage 
in combination with repeated restraint stress. The following sections will address the 
validity in examining PB and modeling stress in a rodent model of GWI. 
Pyridostigmine Bromide in GWI 
In GWI, several different rodent models have emerged with varying advantages 
and limitations. Most notably, the majority of rodent models of GWI use a cocktail of 
chemicals to mimic the vast array of exposures soldiers may have experienced. The 
chemicals included in this cocktail vary across studies and include combinations of low 
levels of nerve gas agents (e.g. diisopropyl fluorophosphate, Sarin, Soman), PB, DEET, 
chlorpyrifos oxon, and permethrin (Abdel-Rahman, Abou-Donia, El-Masry, Shetty, & 
Abou-Donia, 2004; Abdel-Rahman, Shetty, & Abou-Donia, 2002; Abou-Donia et al., 
2004; Locker et al., 2017). While this chemical cocktail can arguably mimic the range of 
conditions soldiers experienced during the Gulf War, the exact contribution PB has 
towards cognitive and physiological outcome measures remains unclear. As such, the 
use of PB in combat conditions remains controversial. The following studies will 
therefore selectively evaluate the contribution of PB in the absence of other chemical 
cocktails to the pathophysiology of GWI.  
Pharmacokinetics and Pharmacodynamics of Pyridostigmine Bromide 
PB was used during the Gulf War due to its effect on the enzymes which 
metabolize acetylcholine - AChE and BChE. PB is hydrolyzed by cholinesterases to 
reversibly inhibit these enzymes in both humans and rats (Jiří, Kuča, & Jun, 2004). By 
binding to the same target on cholinesterases as Sarin and Soman, PB can dramatically 
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increase survival rates in the event of exposure to these irreversible cholinesterase 
inhibitors. The efficacy of PB in this role has been established across a variety of species, 
including rats, mice, guinea pigs, rabbits, and primates (Gordon, Leadbeater, & 
Maidment, 1978; Maxwell, Brecht, Lenz, & O’Neill, 1988; Von Bredow et al., 1991). 
Human dosing regimens were ultimately based on primate studies which determined 
that inhibition of 40-50% of peripheral cholinesterase was sufficient to produce 
significantly greater rates of survival in the event of exposure to Sarin or Soman and that 
increasing the dosage beyond this point did not significantly increase survival (Von 
Bredow et al., 1991). 
Pyridostigmine is a carbamate compound which is stabilized by the addition of a 
bromide salt, resulting in pyridostigmine bromide (PB). PB is water-soluble and 
distributes evenly across a variety of tissues with maximal bioavailability at 
approximately 2 hours after oral administration in humans and 30 minutes in rats 
(Barber, Bourne, Calvey, & Muir, 1975; Marino et al., 1998). The bioavailability of PB 
when administered orally is estimated to be as low as 12% (Marino et al., 1998), which is 
suspected to be due to either poor gastrointestinal absorption or rapid first-pass 
metabolism by the liver.  
Metabolism of PB proceeds via first-order kinetics (Kornfeld, Samuels, Wolf, & 
Osserman, 1970). PB is metabolized by microsomal enzymes (e.g. cytochrome p450) in 
the liver into 3-hydroxy-N-methylpyridinium and excreted in the urine as both the 
metabolite and unaltered pyridostigmine (Yakatan & Tien, 1979). This results in a 
relatively short half-life of PB across species. As such, soldiers were recommended to 
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take 30 mg tablets PB orally every 8 hours for up to 21 days (Madsen, Hurst, MacIntosh, 
& Romano, 2003). Oral administration in humans can be mimicked successfully by 
gavage in rats. Studies have found that a daily dose of 1.3 mg/kg PB in rats reduces 
plasma cholinesterase activity by approximately 50% which matches the target levels in 
soldiers (Abou-Donia et al., 2004). 
Modeling Stress in GWI 
 Soldiers in theater experienced a variety of deployment related stressors 
including uncertainty of tour length, crowded living, harsh climates, sleep deprivation, 
boredom, long work hours, isolation from home culture and comforts, threats from 
biological and chemical warfare, and fear of injury or death, in addition to post-
deployment stressors associated with difficulties readjusting to civilian life (Gifford, 
Ursano, Stuart, & Engel, 2006; Nisenbaum et al., 2000). The stressors from deployment 
are hypothesized to be significant contributing factors to the development of GWI 
symptoms in a way that is unique from stress-contributions to the development of other 
war-related disorders such as PTSD (Robert W. Haley, 1997; Nisenbaum et al., 2000). 
However, variations in soldiers’ experiences, poor reliability of self-report methods, and 
poor record-keeping during war-time makes disentangling the unique contributing 
effects of stress with other factors soldiers experienced during deployment difficult. As 
such, to understand the casual roles and mechanisms by which stress contributes to the 
pathophysiology of GWI, research has turned to preclinical models.  
Although no model can recapitulate the stress of deployment into active combat 
zones, rodent models of GWI have used a variety of stressors in their paradigms. For 
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example, some studies have mimicked stress by adding corticosterone into the animals’ 
drinking water (Locker et al., 2017). Corticosterone is a hormone released by the 
adrenal glands following stress-induced activation of the hypothalamic-pituitary adrenal 
(HPA) axis, and as such, is an important hormone in the stress-response. However, 
stress also activates the sympathetic nervous system and instigates cognitive processing 
of the stressful event. As such, corticosterone alone cannot accurately mimic the 
entirety of the stress response. Other models have subjected rodents directly to 
stressful stimuli. These stimuli vary from forced swim to restraint, to cold stress, to heat 
stress, to avoidance-escape foot-shock stress (Grauer, Alkalai, Kapon, Cohen, & Raveh, 
2000; Kant et al., 2001; Lallement et al., 1998; Servatius et al., 2000; Sinton, Fitch, Petty, 
& Haley, 2000). The effects of stress on physiology are heterogenous with results 
contingent upon both the prior history, the type of stressful stimuli, and the conditions 
under which stressful stimuli are presented, and the brain region or system being 
examined (M. A. Wilson, Grillo, Fadel, & Reagan, 2015). As such, there could be 
variability between different stress models in rodent models of GWI.  
The following studies used six hours a day of repeated restraint stress for the 
course of ten days. This stress paradigm was selected because 1) of all these models of 
stress, psychological stress due to repeated restraint has the most robust and consistent 
literature on behavioral and physiological effects of this type of stress (S. Cook & 
Wellman, 2004; Macht & Reagan, 2017; B.S. McEwen, 2001; Jason J. Radley et al., 2008; 
Watanabe, Gould, & Mcewen, 1992; Wellman, 2001), and 2) the morphological and 
behavioral effects of repeated restraint for this duration are reversible following 
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removal of the stressor or pharmacological intervention (Bloss et al., 2010; Conrad et al., 
1999; Luine et al., 1996, 1994; Magarinos and McEwen, 1995; Magarinos et al., 1999; 
Radley et al., 2005). The reliability of the effects of restraint stress on outcome 
measures make it an ideal stressor by which to assess the synergistic effects of PB and 
stress over time. This way, synergistic effects between PB and stress will not be 
attributable to inconsistent variations in the stress paradigm on outcome measures.  
The nervous system is extremely sensitive to the effects of restraint stress, and 
while acute stress can promote neuroplasticity and facilitate cognitive performance, 
chronic stress has been implicated in a host of cognitive disorders including anxiety, 
major depression, Alzheimer’s, and PTSD. Therefore, it is possible that the chronic stress 
from deployment contributed to the pathophysiology of some of the cognitive 
symptoms evidenced in GWI. For example, the prefrontal cortex (PFC) and hippocampus 
are sensitive to the effects of chronic stress and produce reproducible effects on 
behavior in addition to morphology and spine density of glutamatergic. These brain 
regions are also critical for a variety of cognitive functions, including attentional 
processing, working memory, and long-term memory – all of which are impaired in GWI. 
However, the morphological and behavioral effects of repeated restraint are reversible 
following removal of the stressor (Bloss et al., 2010; Conrad et al., 1999; Luine et al., 
1996, 1994; J.J. Radley et al., 2005). This suggests that stress alone is unlikely to have 
caused the long term and progressive symptoms in GWI. 
Interactions between Pyridostigmine Bromide and Stress on the Blood-Brain Barrier 
Stress is not thought to impact the metabolism or distribution of PB in peripheral 
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tissues (Francesconi, Hubbard, & Mager, 1983). However, an early hypothesis that 
garnered much interest was that stress affects the integrity of the blood-brain barrier, 
creating a “leaking effect” which allows PB to cross into the central nervous system and 
directly alter central cholinesterase activity and consequently, cognitive function. In 
1996, Friedman et al. determined that mice subjected to forced swim stress increased 
the sensitivity of brain AChE messenger ribonucleic acid (mRNA) to PB, such that less 
than 1% of the original dose was required to alter brain AChE activity levels under these 
conditions. This was paralleled by increased excitability of synaptic circuits in the CA1 
region of the hippocampus relative to controls. Other studies suggested that twenty-
eight days of a chemical cocktail of PB, DEET, and permethrin in combination with five 
minutes per day of restraint stress exhibited significant increases in blood-brain barrier 
permeability in a brain-region specific manner with the cingulate cortex, dentate gyrus, 
thalamus and hypothalamus being particularly sensitive, relative to water-treated non-
stressed controls (Abdel-Rahman et al., 2002). Using this same “toxic soup” paradigm, 
Abdel-Rahman et al. (2004) found that the combination of mild restraint stress and 
these toxic chemicals altered brain AChE levels in the midbrain, brainstem, and 
cerebellum. Unfortunately, other studies have failed to replicate these early findings of 
stress-induced blood-brain barrier permeability to PB (Amourette et al., 2009; Grauer et 
al., 2000; Kant et al., 2001; Song, Tian, Bressler, Pruett, & Pope, 2002; Tian, Song, 
Bressler, Pruett, & Pope, 2002). As such, it remains unclear whether stress disrupts the 
blood-brain barrier to allow PB to directly impact central neurotransmitter function.  
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The Immune System as the Crossroads between Pyridostigmine Bromide and Stress 
Even if PB does not cross the blood-brain barrier, clinical (Golier, Schmeidler, 
Legge, & Yehuda, 2007; Nisenbaum et al., 2000; L Steele et al., 2012; Sullivan et al., 
2003) and preclinical (Amourette et al., 2009; Hattiangady et al., 2014) studies have 
supported indirect synergistic effects of PB and stress on cognitive function, suggesting 
that PB may interact with stress through peripheral systems to alter central neurological 
function. Exactly which systems PB and stress interact on and how this feeds back to 
impact the brain and behavior is currently unknown; hence, characterizing the 
interactions between stress and PB on peripheral systems and determining how this 
correlates with behavior is an important precursor to determining the effects of stress 
and PB on the central nervous system.  
The following set of studies were based on the hypothesis that the immune 
system provides the mechanistic link by which peripheral effects of PB interact with 
chronic stress to produce changes in neural function in the brain. This section will 
discuss four primary pieces of evidence which led to this hypothesis: 1) stress and PB 
both independently impact immune function, 2) veterans with GWI exhibit changes in 
the HPA axis and immunological markers that are consistent with those seen in 
preclinical chronic stress paradigms, 3) preclinical models using PB have found both 
central and peripheral immune changes, and 4) the cholinergic anti-inflammatory 
pathway may provide the immunological link by which PB could interact to impact 
central nervous system function without crossing the blood-brain barrier. 
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One classic study linking stress to the immune system emerged in 1987 with the 
finding that medical students exhibited immunosuppression and increased sickness 
behaviors during their examination period (Glaser et al., 1987). In the decades since, 
multiple studies have worked to elucidate the bi-directional interactions between stress 
and the immune system, resulting in a multifold increase in neuro-immune publications 
over the last two decades (Quan & Banks, 2007). There are two major pathways by 
which stress directly affects immune function: the HPA axis and the catecholamine-
driven sympathetic nervous system (Besedovsky, Rey, Sorkin, Da Prada, & Keller, 1979). 
Both the HPA axis and the sympathetic nervous system are activated during the stress 
response, and chronic activation of these systems results in chronic production of both 
glucocorticoids and catecholamines (Padgett & Glaser, 2003). A variety of immune cells 
express receptors for both glucocorticoids and catecholamines, and the sympathetic 
nervous system directly innervates lymph nodes, suggesting that the HPA axis and 
sympathetic nervous system have multiple regulatory points on the immune response 
(Besedovsky et al., 1979; del Rey, Besedovsky, Sorkin, da Prada, & Arrenbrecht, 1981; 
Gametchu, Watson, & Wu, 1993). 
Similarly, the immune system also influences neural function in the CNS, 
highlighting that this stress-immune dynamic is bidirectional (Miller, Galpern, Dunlap, 
Dinarello, & Turner, 1991; Plata-Salamán & Ffrench-Mullen, 1992). The central effects of 
cytokines on neurotransmitter systems were first directly recorded in amino acid 
neurotransmitter systems, GABA and glutamate (Miller et al., 1991; Plata-Salamán & 
Ffrench-Mullen, 1992). While these cytokine-mediated effects on amino acid 
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neurotransmitter systems were originally thought to be driven by cytokines released by 
immunocompetent cells in the central nervous system – microglia and astrocytes – 
research suggests that peripheral cytokines can may also impact central 
neurotransmitter system function by crossing the blood-brain barrier though a saturable 
transport system (Banks, Kastin, & Broadwell, 1995; Habif, Lipton, & Cantell, 1975). This 
suggests that peripheral and central cytokine signaling cues can both potentially 
influence neurotransmitter function in the central nervous system. 
A third and critical point of interaction between the periphery and central 
nervous system regulation of the immune response resides in the vagal nerve anti-
inflammatory reflex (V. Pavlov, Wang, Czura, Friedman, & Tracey, 2003). This reflex was 
originally discovered after it was reported that stimulation of the vagus (“wandering”) 
nerve inhibits the macrophage production of the cytokine TNF-α following 
administration the endotoxin lipopolysaccharide (LPS) (Borovikova et al., 2000). The 
vagus nerve is a critical point of communication between the central and peripheral 
nervous systems. Vagal efferents directly regulate the peripheral immune response 
while vagal afferents relay information to the central nervous system on the state of 
inflammation in the periphery (Rosas-Ballina & Tracey, 2009). In GWI, the effects of 
chronic stress may be compounded by PB interactions at the cholinergic anti-
inflammatory pathway of the vagus nerve (Bauer, Perks, Lightman, & Shanks, 2001). 
Vagus nerve efferents release acetylcholine which binds to nicotinic α7 receptors on 
peripheral macrophages to decrease the production of a variety of pro-inflammatory 
cytokines, particularly TNF-α (Tracey, 2002). Since PB inhibits ChE, chronic 
17 
administration of PB may have altered the immune system by increasing the effects of 
acetylcholine at nicotinic α7 receptors on both macrophages and the adrenal glands, 
thereby altering both peripheral immune signals and feedback cues to the central 
nervous system via vagal afferents. 
Collectively, these studies suggest that the interplay between the central and 
peripheral nervous system, immune system, and endocrine system is complex with the 
function of each system depending on input from the others. This has important 
implications for clinical pathologies as differences in the dysregulation of each neuro-
immune and endocrine system can be associated with different clinical states. 
Endocrine and Immune Dysfunction in GWI 
Veterans with GWI exhibit alterations in both endocrine and immune systems 
that are distinct from other war-related (PTSD) and non-war related (chronic fatigue 
syndrome) disorders, suggesting that despite overlapping symptomology, GWI 
symptoms are driven by unique mechanisms. For example, Golier et al., (2007) 
determined that GWI but not PTSD was associated with low levels of 
adrenocorticotropic hormone (ACTH) and consequently a higher cortisol: ACTH ratio. 
This unique endocrine profile in veterans with GWI was also positively correlated with 
the presentation of both PB treatment and cognitive symptoms. In addition, Whistler et 
al., (2009) determined that the cortisol response to an exercise challenge was 
dampened in individuals with GWI relative to the control group - sedentary veterans 
from the National Guard. Collectively, these studies suggest that GWI is characterized at 
least in part by dysregulation of the HPA axis. 
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GWI is also repeatedly associated with shifts in the immune system, although 
specific cytokine shifts are often inconsistent between studies. For example, unlike in 
chronic fatigue syndrome, fatigue symptoms in GWI have not been associated with 
increased IL-1β, a pro-inflammatory cytokine classically associated with fatigue in 
sickness (Parkitny, Middleton, Baker, & Younger, 2015). Veterans with GWI do exhibit 
decreases in natural killer cell number and sensitivity to cytotoxicity in addition to 
elevations in the cytokine interleukin (IL)-5 compared to sedentary control veterans 
during an exercise challenge (Whistler et al., 2009). Preclinical studies have confirmed 
that PB decreases natural killer cell activity and T-cell dependent antibody 
responsiveness, suggesting that these cytokine shifts in clinical populations may have 
been driven by PB (Peden-Adams et al., 2004). In contrast, Broderick et al. (2011) found 
a heightened IL-2, IL-10, IFN-γ, and TNF-α response to an exercise challenge in GWI 
relative to healthy controls but not non-veteran subjects with chronic fatigue syndrome. 
While part of these differences may be attributable to differences in control populations 
or other experimental parameters, other evidence suggests that the immune system in 
veterans with GWI is extremely variable from day to day relative to healthy veterans 
who served in the Gulf War (Parkitny et al., 2015). As such, while shifts in immune 
parameters in GWI are undoubtedly a critical component of this illness, exactly what 
those shifts are, under what experimental conditions, and how those shifts contribute to 
the presentation of symptoms in GWI remain to be elucidated. Animal models of GWI 
which examine shifts in endocrine and immune systems under basal conditions and in 
response to stressful stimuli could help clarify these findings. 
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These alterations to the peripheral immune system by both stress and PB could 
have altered feedback to the central nervous system, potentially resulting in synergistic 
effects of stress and PB on both immune function and neural networks. In support of 
this idea, a preclinical model of GWI using a combination of stress and variety of Gulf 
War chemicals (i.e. DEET, permethrin, PB) suggested that the combination of Gulf War 
chemicals and stress resulted in greater density of microglia and astrocyte hypertrophy 
in the hippocampus than Gulf War chemicals alone. This provides evidence that stress 
and Gulf War chemicals exhibit synergistic effects on the immune system that are 
evident in the central nervous system (Parihar et al., 2013). While this study provides 
insight into possible central nervous system effects of Gulf War conditions, the 
combination of multiple chemicals makes isolation of the effects of PB impossible to 
untangle. 
Based on these studies, the following experiments examined interactions 
between stress and PB on the immune system and on neural function. In light of the 
clinical studies suggesting that immune effects in GWI are exacerbated when 
challenged, the following experiments used a preclinical model of GWI to examine 
physiological and behavioral effects under both basal conditions and following a 
challenge (e.g. LPS, restraint stress). 
Overarching Experimental Hypotheses 
The following research aims to assess the mechanism by which PB and stress 
could interact to cause GWI symptomology in a rodent model. The overarching general 
hypotheses for the following experiments are that 1) chronic stress interacts with PB to 
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adversely impact homeostasis of peripheral endocrine, cholinergic, and immune systems 
in a progressive manner, and 2) chronic stress interacts with PB to adversely impact 
central neurotransmitter responses to future stressful stimuli. To address these 
hypotheses, the following work is divided into three separate experiments which are 
addressed in the following chapters. The first set of experiments (Chapter 2) test the 
progression of peripheral and behavioral consequences to repeated psychological 
(restraint) stress and PB. The second and third sets of experiments (Chapters 3 and 4, 
respectively) test neurochemical changes to an LPS and acute restraint stress challenge 
using the GWI paradigm. Specific hypotheses for each experiment will be addressed in 
each subsequent chapter. 
 
1.3 EXPERIMENTAL DESIGN 
The following experimental design encompasses the general animal model of 
GWI which provided the basis for all subsequent studies. More specific methods, 
relating to each individual set of experiments, will be provided in the appropriate 
corresponding chapters. 
Animal Housing 
All studies used young adult male Sprague Dawley rats which were individually 
housed at the University of South Carolina School of Medicine’s animal facility in a 
temperature-controlled facility (22oC) with 12/12 h light-dark cycle with lights on at 7:00 
AM and ad libitum access to food and water. Although both males and females have 
reported GWI, this study used males since the majority of soldiers and hence incidences 
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of GWI were in men (Nettleman, 2015). For all studies, rats habituated to the animal 
facility for one week prior to the start of the experiments. After a week of acclimation to 
the animal facility, each rat was randomly assigned to a treatment condition for 
subsequent studies (Figure 1.1). Experiments ranged from approximately one to three 
months in duration. All housing procedures for these experiments are in accord to all 
guidelines and regulations by the University of South Carolina’s Animal Care and Use 
Committee.  
GWI Paradigm  
Because preclinical studies determined that PB is only effective when 
administered chronically prior to the onset of nerve gas agent exposure (Gordon et al., 
1978; Von Bredow et al., 1991), soldiers were authorized to take PB before deployment 
if they were being sent to high risk zones (Madsen et al., 2003). Animal models assessing 
the contribution of PB to GWI must therefore recapitulate this repeated dosing 
paradigm with PB treatment preceding stress. The current study therefore used a 
paradigm of 4 days of 1.3 mg/kg/day PB treatment by oral gavage followed by a 
combination of PB with 10 days of restraint stress. Rats were weighed every other day 
at 9:00 AM to ensure accurate dosing. PB was prepared fresh daily in sterile water with 
a final concentration of 0.13 mg/mL. Rats were gavaged daily with either water or PB 
between 9:30-10:00 AM.  
On day 5 of treatment, rats were randomly assigned to either repeated restraint 
stress (stress) or non-stressed conditions (NSC). Stressed rats were housed separately 
from non-stressed controls and placed in wire mesh restrainers from 10:00 AM to 4:00 
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PM on treatment days 5-14. Restraint lasted six hours as this duration increases 
hippocampal vulnerability in a manner not observed with shorter daily stress durations 
(McLaughlin, Gomez, Baran, & Conrad, 2007; M. A. Wilson et al., 2015). Restrainers had 
painted rubberized edges for protection. Once the rats were placed in the restrainers, 
the ends were secured with clips to keep the rat in from escaping while permitting small 
movements (as described in Reznikov et al., (2008) and Reagan et al., (2004)). Tail 
bleeds were performed on day 14 of treatment for all rats, approximately 30 minutes 
after the onset of restraint stress. At the end of treatment, rats were assigned to either 
early or delayed evaluation time points (Figure 1.2). As such, the rats comprising the 
early or delayed time point are separate cohorts of animals. For euthanasia, rats were 
lightly anesthetized with isoflurane, after which trunk blood was collected for all 
experiments at early (day 24) and delayed (day 104) time points for further analyses. 
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Figure 1.1. Experimental Groups. This 
experiment had a 2×2 design with 2 levels 
of drug treatment (vehicle, PB) and 2 levels 
of stress (NSC, stressed). PB is prepared 
fresh daily in sterile water with a final 
concentration of 0.13 mg/mL.  
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Figure 1.2 Timeline for Gulf War Illness Paradigm. All rats underwent the GWI 
paradigm with 2 levels of drug treatment (vehicle, PB) and 2 levels of stress (non-
stressed control, repeated restraint stress). PB treatment preceded the beginning 
of the stress paradigm by 4 days. Between 9:30-10:00 AM, rats were gavaged 
with either vehicle or PB. On the 5th day of treatment, rats undergoing restraint 
stress were moved to a separate room for restraint stress. Rats were placed in 
wire mesh restrainers at approximately 10:00 AM, just after gavage. Restraint 
stress lasted 6 hours per day for a total of 10 days. The entirety of the treatment 
paradigm lasted 14 days. 
Day 5 Day 1 
± Repeated Restraint Stress 
± PB Treatment 
Day 14 
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CHAPTER 2 
EXPERIMENT ONE: GULF WAR ILLNESS FROM PHYSIOLOGY TO BEHAVIOR
Although GWI is considered unique to the Gulf War, symptomology of GWI 
parallels symptoms of other conditions in civilian populations, including chronic fatigue 
syndrome, major depression, PTSD, and fibromyalgia. However, epidemiological studies 
have consistently demonstrated that the underlying physiology driving these symptoms 
is unique in GWI. For example, although both chronic fatigue syndrome and GWI exhibit 
altered immune functions, the cytokine profiles in both populations are distinct (G. J. 
Johnson, Slater, Leis, Rector, & Bach, 2016; Khaiboullina et al., 2015; Parkitny et al., 
2015; Smylie et al., 2013).  
Endocrine profiles are also altered in veterans with GWI. Veterans with GWI 
exhibit exaggerated cortisol suppression in response to a low dose of dexamethasone 
relative to non-deployed veterans when PTSD, smoking, weight, and depression are 
taken into account (Golier, Schmeidler, Legge, & Yehuda, 2006). Veterans with GWI also 
exhibit a significant elevation in their cortisol to ACTH ratios, further emphasizing 
dysregulation of endocrine systems in this population (Golier et al., 2007). Predictive 
computational models of GWI have suggested that 1) GWI in males is characterized by 
disruption of homeostatic states which consist of hypercortisolism and a shift towards a 
pro-inflammatory immune profile, and 2) persistence of clinical symptoms across the 
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decades is perpetuated by continued disruption of these homeostatic systems 
(Craddock et al., 2014). One of the primary hypotheses of the computational model of 
GWI is that under normal physiological conditions where a challenge is presented (e.g. 
stress, drug exposure, etc.), systems respond to the event and then return to prior basal 
levels. However, when a disruption is of significant duration and magnitude, the system 
assumes a new resting state. In some cases, this new resting state can be maladaptive. 
In the case of GWI, a shift in the resting state of physiological parameters may underlie a 
variety of clinical symptoms evidenced in this population. 
Hypotheses 
The aim of the current study was to assess whether the pathogenesis of PB and 
stress-induced changes in physiological markers – immune, endocrine, cholinergic – 
paralleled changes in behavior. Specifically, on the last day of treatment, we 
hypothesized that cholinesterase activity would be reduced in PB treated rats, that 
corticosterone would be increased in rats undergoing restraint stress, and that PB would 
attenuate the inflammatory response to stress in PB-stressed rats. In addition, because 
veterans with GWI exhibit progressive symptom severity, we hypothesized that the 
combined effects of PB and stress on these parameters would become exacerbated over 
time. We therefore examined the effect of PB and stress on each of these measures at 
three separate time points: on the last day of treatment, ten days following the 
cessation of treatment, and three months following the cessation of treatment. PB and 
stress effects on peripheral cytokines were hypothesized to be the most sensitive to the 
27 
interactive effects of PB and stress due to the abundant evidence of immune 
dysfunction in veterans with GWI. Thus, this study expands upon data from 
epidemiological and computational models by providing causal evidence for the role of 
PB and stress in the pathophysiology of GWI. In addition, we examined the effects of PB 
and stress on fear conditioning to determine whether shifts in these physiological 
parameters paralleled shifts in cognitive function. Because veterans with GWI exhibit 
significant memory deficits in a manner that is independent from PTSD symptom 
presentation, we hypothesized that fear conditioning will be impaired in rats which 
received a combination of PB and repeated restraint stress and that these deficits will 
become exacerbated over time. 
 
2.1 METHODS AND MATERIALS 
The first experiment examined the progression of GWI from a variety of 
peripheral measures: cholinesterase activity, corticosterone, and cytokines. These 
measures were assessed at three different time points: day 14 of treatment (acute), 
one-week post-treatment (early), and three months post treatment (delayed) (Figure 
2.1). Early and delayed time points consisted of separate cohorts of animals with N = 
106 for the entire study.  
Plasma Collection 
Tail bleeds from the acute time point were taken 30 minutes following 
administration of drug treatment and onset of stress. Trunk blood was also collected on 
ice in EDTA-treated tubes during euthanasia for both the early (Day 24) and delayed 
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Figure 2.1 Timeline for Experiment One. All rats underwent the GWI paradigm 
with 2 levels of drug treatment (vehicle, PB) and 2 levels of stress (non-stressed 
control, repeated restraint stress). Thirty minutes following gavage on day 14, all 
rats underwent a tail bleed to assess plasma levels of AChE activity, 
corticosterone, and levels of 12 different cytokines. Following, rats were further 
subdivided into either early or delayed conditions. Rats in the early condition 
underwent conditioned freezing on Days 20-21 and were euthanized followed by 
perfusion on Day 24 (n = 13 per group). Rats in the delayed condition went 
through conditioned freezing on days 100-101 and euthanized followed by 
perfusion on day 104 (n = 13-14 per group). Plasma from the trunk blood was 
then assessed for each of these peripheral measures at these time points.  
Day 5 Day 1 
± Repeated Restraint 
 ± PB Treatment 
Day 14 
AChE Activity Assay 
Corticosterone Assay 
Cytokine Assay 
Euthanasia 
AChE Activity Assay 
Corticosterone Assay 
Cytokine Assay 
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AChE Activity Assay 
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Cytokine Assay 
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(Day 104) time points. Importantly, all plasma measures from early and delayed time 
points were conducted on animals which had undergone fear conditioning. However, a 
substantial recovery period was allocated between fear conditioning and euthanasia. 
For euthanasia, 6-7 rats per group which had gone through fear conditioning were 
lightly anesthetized and then transcardially perfused with 0.1 M phosphate buffered 
saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer. The remaining rats 
in each group were rapidly decapitated for a separate study. All blood was collected on 
ice and then spun down for 15 minutes at 13,000 x g. Plasma supernatant was removed 
from each vial and frozen at -80oC. 
Contextually-Conditioned Freezing 
 The conditioned freezing paradigm was performed as described previously 
(Sharko, Fadel, Kaigler, & Wilson, 2017). For rats in the early cohort, behavioral testing 
was performed from days 17-20. For rats in the separate, delayed cohort, behavioral 
testing was performed from days 97-100. During the light phase on each test day, rats 
were transported to the behavioral testing suite where they were placed in a 46 x 24 x 
22 cm acoustically isolated shock box. For the acquisition phase, rats were exposed to 
the testing box for 3 min to assess unconditioned freezing in the novel context. Rats 
were then given three 10 sec tones (2 KHz, 80 dB) that co-terminated with a 1 second, 1 
mA shock at 1 minute inter-stimulus intervals. Twenty-four hours following acquisition 
of the fear response, rats were returned to the testing box in the absence of tones or 
shocks for a total of 8 minutes. The chamber was wiped clean with 5 % ammonium 
hydroxide in between each rat’s test period during both test days. All tests were 
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recorded on video tapes using FreezeScan (Clever Systems, Inc). Freezing was defined as 
the absence of movement excluding respiration. For both acquisition and contextual 
freezing, percent freezing behavior was automatically assessed in 1 min bins using 
FreezeScan software. Accuracy of automated software was verified by a blind observer. 
Cholinesterase Assay 
A cholinesterase activity assay measuring AChE and BChE activity was performed 
on plasma from tail bleeds (day 14) and on trunk blood at early (day 24) and delayed 
(day 104) time points using the Abcam acetylcholinesterase assay kit (#ab138871). All 
components of the acetylcholinesterase assay kit were thawed to room temperature 
prior to use. Standards were 300, 100, 30, 10, 3, 1, and 0 mU/mL. 50 µL of standards and 
samples were added to the 96-well plate in duplicates. Then 50 µL of acetylthiocholine 
reaction mixture was added to each well, following which the plate incubated at room 
temperature for 20 minutes, protected from light. The plate was read using a microplate 
reader at 410 nm absorbance settings. Cholinesterase activity from samples was 
interpolated from the linear standard curve. Due to assay to assay variability, data at 
each time point were expressed as a percentage of the mean of their respective vehicle-
NSC groups in order to allow clear interpretations of the data, where the mean 
cholinesterase activity across all assays for vehicle-NSC rats was 43.03 ± 2.30 mU/mL. 
Corticosterone Assay 
 Plasma corticosterone was assessed using a corticosterone ELISA kit from Enzo-
Life Sciences (#ADI-900-097) on plasma from tail bleeds (day 14) and on trunk blood at 
early (day 24) and delayed (day 104) time points. All components of the assay kit were 
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brought to room temperature prior to use. Samples were diluted 1:40 with steroid 
displacement reagent and kept on ice. Standards were 20,000, 4,000, 800, 160, and 32 
pg/mL corticosterone and prepared using standard diluent. 100 µL of either the samples 
or standards were then added in duplicate to each well. Standard diluent was pipetted 
into the non-standard blank (NSB) and B0 wells. Subsequently, 50 µL of alkaline 
phosphatase conjugated with corticosterone was added to each well except total 
activity and blank wells, after which 50 µL of polyclonal sheep anti-corticosterone 
antibody was pipetted into each well except total activity, NSB and B0 wells. The plate 
was then sealed and placed on an orbital shaker for 2 hours at 500 rpm. Plate contents 
were then washed 3X3 times with wash buffer. 5 µL of alkaline phosphatase conjugated 
with corticosterone was added to the total activity wells, after which 200 µL pNpp 
substrate solution was added to every well. The plate was then incubated a second time 
for 1 hour without shaking. 50 µL of stop solution was added to each well to stop the 
reaction, after which the plate was immediately read using a microplate reader at 590 
nm absorbance. Corticosterone activity was interpolated from standards using a 4-
parameter logistic curve.  
Cytokine Assay 
A rat cytokine assay kit from Bio-Plex (#171k1002M) was used to quantify 
immune molecules in plasma from tail bleeds (day 14) and trunk blood at early (day 24) 
and delayed (day 104) time points. The Bio-Plex assay uses premixed coupled magnetic 
beads and detection antibodies to detect 12 different rat cytokines. Solutions for the 
assay were brought to room temperature 30 minutes prior to initiation of assay 
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procedures. Eight four-fold dilution standards were prepared using the provided diluent 
and reconstituted standard, and samples were thawed and diluted 1:4 with diluent. 288 
µL of 20x beads were vortexed for 30 seconds and then diluted with 5472 µL of assay 
buffer for a total volume of 5760 µL. 50 µL of the diluted beads were then added to be 
bottom of a 96-well plate, followed by 50 µL of standards and samples. The assay plate 
incubated on an orbital shaker plate for 1 hour at room temperature. After 3 washes 
with wash buffer, 25 µL of detection antibody was added to each well, followed by a 30-
minute incubation at room temperature on an orbital shaker. The detection antibody 
was washed from the plate with 3 washes using wash buffer. 50 µL of SA-PE was added 
to each well and the plate was incubated on an orbital shaker at room temperature for 
10 minutes. After the incubation, the plate was washed 3 times with wash buffer and 
then the beads were re-suspended in 125 µL assay buffer. After 30 seconds, the plate 
was read on a Luminex Bio-Plex Multiplex plate reader using high photomultiplier 
voltage. Results were interpreted from a logarithmic standard curve. Due to assay to 
assay variability, data at each time point were expressed as a percentage of the mean of 
their respective vehicle-NSC groups in order to allow clear interpretations of the data. 
Statistical Analyses 
All data unless otherwise specified was analyzed using a 2 X 2 between-groups 
analysis of variance (ANOVA) with significance set at α = 0.05. The between groups 
factors were drug treatment (i.e. vehicle, PB) and stress (i.e. non-stressed control, 
repeated restraint stress). Early and delayed groups were analyzed separately as 
determined a priori. Sample size was determined by power analysis for behavioral 
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studies and suggested that 13 animals per group were sufficient to achieve statistical 
significance given an effect size of f = 0.6 and α = 0.05. As behavioral measures exhibit 
the most variability, N-sizes for plasma measures were the same as those of behavior. 
Cytokines were analyzed as a multivariate ANOVA with univariate ANOVA as a 
post-hoc follow-up when appropriate. Contextually conditioned freezing behavior was 
analyzed using a repeated measures ANOVA with the addition of the factor time in 
conjunction to the factors of treatment and stress. Following significant interactions, 
simple effects tests were performed with Bonferroni post-hoc corrections for family-
wise error. 
 
2.2 RESULTS 
Contextually-Conditioned Freezing 
 Contextually-conditioned freezing was first assessed at the early time point, 
approximately one-week after the cessation of drug and stress exposure. During the first 
day (acquisition) of the contextually-conditioned freezing paradigm, freezing increased 
with the three tone-shock pairings, as expected, F(5, 240)=490.0, p < 0.001. This 
suggests that all rats appropriately acquisitioned the fear response. Twenty-four hours 
following acquisition of the fear response, rats were returned to the testing box in the 
absence of tones or shocks for a total of eight minutes. Contextual freezing was 
impacted by time, F(7, 336)=25.79, p < 0.001. Freezing behavior increased incrementally 
over the first three minutes, (p < 0.001 and 0.001, respectively). There was also a main 
effect of stress such that stress decreased context-associated freezing, F(1, 48)=7.34, p = 
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0.009. Follow-up analyses determined that this effect is driven by the group which 
received PB in addition to stress where PB-stress rats froze less than NSC counterparts 
during the first 4 time points (p = 0.004, 0.004, 0.004, and 0.036, respectively). This 
suggests that while there is a main effect of stress on conditioned freezing, this deficit in 
context-associated fear conditioning is primarily driven by rats which were stressed and 
received PB (Figure 2.2).  
At the delayed time point, freezing increased with the three tone-shock pairings, 
F(5, 240)=641.7, p < 0.001 (Figure 2.3). These data indicate that all rats appropriately 
acquired the fear-response. Twenty-four hours later, rats were returned to the testing 
box in the absence of tones or shocks for a total of eight minutes. Results indicate that 
time significantly affected contextual freezing within all groups, F(7, 366)=15.42, p < 
0.001. Specifically, freezing increased incrementally from minutes 1-3, (p < 0.001 and 
0.001, respectively). There was also a trend for a stress × time interaction, F(7, 
350)=1.81, p = 0.08, and a stress × drug interaction, F(1, 50)=3.82, p=0.056. Specifically, 
prior history of stress increased freezing during the first three minutes in vehicle-treated 
but not PB-treated rats relative to vehicle-NSC rats (p = 0.001, 0.007, and 0.049, 
respectively). These results suggest that a prior history of restraint stress in the absence 
of PB treatment sensitizes the contextual conditioned fear response. 
Cholinesterase Assay 
PB decreased plasma cholinesterase activity by approximately 50% relative to 
vehicle-treated controls on the last day of drug treatment (day 14), F(1, 23)=69.40, p < 
0.001 (Figure 2.4). This reduction in cholinesterase activity following PB administration   
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Figure 2.2. Conditioned Freezing One Week Post-Treatment. Panel A. There was no 
effect of any factor on acquisition of freezing behavior in response to three shocks. 
This suggests that neither stress nor PB impacts learning of fear memory at this time 
point. Panel B. Stressed rats froze less in the context where the shocks had occurred 
relative to NSC rats. Further analysis indicates that this effect is driven by the 
condition in which rats received PB and stress, suggesting that PB may exacerbate 
the effects of stress on consolidation or recall of fear memories. Results are 
expressed as group mean percent freezing ± SEM at each time point.  
A: *: significant effect of time on freezing behavior relative to previous time point, p 
< 0.05; ↓: 1 second shock paired with a 10 second tone  
B: *: significant effect of stress in PB-treated rats, p < 0.05. 
A. 
 
 
 
 
 
 
 
B. 
↓       ↓       ↓ 
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Figure 2.3. Conditioned Freezing Three Months Post-Treatment. Panel A. There was 
no effect of any factor on acquisition of freezing behavior in response to three shocks. 
This suggests that neither stress nor PB impacts learning of fear memory at this time 
point. Panel B. Rats with a prior stress history without PB treatment froze more in the 
context where the shocks occurred, suggesting that a prior stress history sensitizes the 
fear response. Results are expressed as group mean percent freezing ± SEM at each 
time point.  
A: *: significant effect of time on freezing behavior relative to previous time point, p < 
0.05;↓: 1 second shock paired with a 10 second tone  
B: *: significant effect of stress in vehicle-treated rats, p < 0.05. 
 
A. 
 
 
 
 
 
 
 
 
B. 
↓       ↓       ↓ 
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aligns with the targeted cholinesterase activity in soldiers whom were administered PB, 
suggesting that the dose of PB administered here accurately reflects that received by 
the target population. At the time of euthanasia for the early cohort (10 days following 
the cessation of treatment), rats treated with PB continued to exhibit a significant, 15% 
decrease in plasma cholinesterase activity relative to vehicle-treated controls, F(1, 
32)=5.82, p = 0.02. Conversely, at the delayed time point, approximately 3 months 
following the cessation of PB treatment, there was a significant effect of PB on 
cholinesterase activity, F(1, 32)=4.88, p = 0.04. Specifically, PB-stressed rats exhibited a 
30% increase in plasma cholinesterase activity relative to vehicle-treated controls, p = 
0.031. These data suggest that stress and PB interact over time to influence peripheral 
levels of cholinesterase activity. 
Corticosterone Assay 
Corticosterone was significantly elevated 30 minutes into restraint on the last 
day of treatment (day 14) in both vehicle and PB treated rats undergoing restraint stress 
relative to non-stressed controls, F(1, 33) = 12.38, p = 0.001 (Figure 2.5). Interestingly, 
corticosterone remained above baseline in rats exposed to restraint stress regardless of 
drug treatment ten days following the cessation of the stress paradigm (early group), 
F(1, 30) = 16.21, p < 0.001. Three months following the cessation of treatment, there 
was an interaction between stress and drug treatment on plasma corticosterone levels, 
F(1, 29) = 7.165, p = 0.01. Corticosterone was significantly elevated in rats with prior 
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Figure 2.4. Plasma Cholinesterase Activity. Panel A. PB decreased plasma acetylcholinesterase activity by 
approximately 50%, which is proportional to pharmacological target values of soldiers. This plasma was 
taken on the last day of PB treatment. Panel B. PB treatment continued to decrease plasma 
acetylcholinesterase activity by approximately 15% ten days following the cessation of treatment. This 
suggests that while PB has a persistent effect, acetylcholinesterase activity following PB-treatment has 
begun to normalize. Panel C. Three months following the cessation of treatment, acetylcholinesterase 
activity is elevated selectively in rats which were exposed to restraint stress in conjunction with PB. This 
suggests that PB and stress interact to produce long-term disruption in the metabolism of peripheral 
acetylcholine. All data are expressed as a percentage of vehicle-NSC rats. Values are expressed as mean± 
SEM at each time point. 
*: significant difference between designated groups, p < 0.05. 
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Figure 2.5. Plasma Corticosterone. Panel A. During the first thirty minutes of restraint stress on the last day of 
the restraint stress paradigm, stressed rats have significantly higher levels of corticosterone than non-stressed 
rats. Panel B. Rats with a prior stress history have elevated corticosterone. This is ten days after the end of the 
restraint stress paradigm and 72 hours following context-retrieval of conditioned freezing. Panel C. Three months 
following the cessation of treatment, corticosterone is elevated selectively in rats which were exposed to 
restraint stress in conjunction with PB relative to non-stressed counterparts. This is also 72 hours following 
context-retrieval of conditioned freezing. Collectively, these data suggest that the effects of PB and stress on 
corticosterone change over time. Values are expressed as mean± SEM at each time point. 
*: significant difference between designated groups, p < 0.05. 
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history of PB treatment in conjunction to chronic restraint stress relative to PB-NSC rats, 
p = 0.029. While prior exposure to the fear conditioning paradigm could be partially 
attributable to these increases in corticosterone, these data suggest that stress and PB 
interact to influence plasma corticosterone differently over time, even in the absence of 
continuation of chronic restraint stress and drug treatment.  
Cytokine Assay 
On day 14, approximately 30 minutes into the restraint stress session, there was 
a significant interaction between PB and stress on levels of IL-1α [F(1, 30) = 5.51, p = 
0.03], IL-1β [F(1, 30) = 6.92, p = 0.01], IL-2 [F(1, 30) = 4.37, p = 0.04], IL-5 [F(1, 30) = 6.23, 
p = 0.02], IL-6 [F(1, 30) = 4.92, p = 0.03], IL-10 [F(1, 30) = 5.75, p = 0.02], IL-12 [F(1, 30) = 
5.41, p = 0.03], IL-13 [F(1, 30) = 6.19, p = 0.02], GM-CSF [F(1, 30) = 6.57, p = 0.02], IFN-γ 
[F(1, 30) = 4.69, p = 0.04], and TNF-α [F(1, 30) = 5.33, p = 0.03] (Table 2.1). The only 
cytokine not impacted by either stress or drug treatment was IL-4, p = 0.74. Follow-up 
ANOVAs revealed that relative to vehicle-NSC rats, both PB-NSC and vehicle-stressed 
rats exhibit increased plasma levels of IL-1α (p = 0.002, 0.007), IL-1β (p = 0.002, 0.015), 
IL-2 (p = 0.027, 0.046), IL-5 (p = 0.001, 0.003), IL-10 (p = 0.003, 0.049), IL-12 (p = 0.008, 
0.029), IL-13 (p = 0.001, 0.016), GM-CSF (p = 0.004, 0.017), and IFN-γ (p = 0.002, 0.041). 
However, only PB-NSC rats exhibited significant elevations in IL-6 (p = 0.003) and TNF-α 
(p =0.017). These results suggest that in NSC conditions, PB can mimic the effects of 
stress on many plasma cytokines. In addition, these results suggest that PB exhibits a 
selective pro-inflammatory effect on IL-6 and TNF-α with PB producing the largest effect 
on levels of IL-6. Interestingly, PB treatment in combination with stress blocked these 
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increases in plasma cytokines, suggesting that PB produces anti-inflammatory effects 
only in the context of another pro-inflammatory stimulus.  
 Ten days following the cessation of treatment, there was no effect of either PB 
or stress on any plasma cytokine (p = 0.715 and 0.692, respectively; Table 2.2). This 
suggests that shortly after the cessation of PB and stress exposure, effects on plasma 
cytokines have normalized at basal conditions. However, three months following the 
cessation of PB and stress exposure, a different picture emerges (Table 2.3). At this 
delayed time point, PB and stress interact to affect plasma levels of IL-1α [F(1, 22) = 
5.09, p = 0.03], IL-2 [F(1, 22)=4.47, p =0.046], IL-4 [F(1, 22)=4.42, p =0.047], IL-6 [F(1, 
22)=5.70, p =0.03], IL-10 [F(1, 22)=4.88, p =0.04], ], IL-12 [F(1, 22) = 4.34, p = 0.049], and 
IFN-γ [F(1, 22) = 4.87, p = 0.04]. Specifically, PB-NSC rats exhibit a decrease in IL-1 α (p = 
0.041), IL-2 (p = 0.008), IL-4 (p = 0.019), IL-6 (p = 0.020), IL-12 (p = 0.038), and IFN- γ (p = 
0.045) relative to vehicle-NSC rats. There is a crossover interaction between PB and 
stress on levels of IL-10, where PB-NSC and vehicle-stressed rats exhibit a decrease in 
these cytokines relative to vehicle-NSC and PB-stressed rats (p = 0.072 and 0.086, 
respectively). In addition, there is a main effect of PB on TNF-α such that a prior history 
of PB regardless of stress history, decreases plasma levels of TNF-α [F(1, 22)=5.40, p = 
0.03].  
 Collectively, these data suggest that the effects of PB and stress are highly 
contingent upon time. During treatment, PB in the absence of stress produces 
significant increases in a variety of cytokines – both pro- and anti-inflammatory. Any 
effect of PB or stress on basal levels of plasma cytokines have disappeared by one-week 
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post-treatment. Conversely, three months post treatment, rats which received PB but 
not stress exhibit reduced levels of circulating cytokines. This could be an over-
compensatory adaptation by the immune system in response to the acute effects of PB, 
suggesting that PB progressively disrupts homeostasis of plasma cytokines. 
 
Table 2.1 Cytokine Levels at Day 14 of Treatment as a Percent of Vehicle—NSC 
Cytokine Vehicle-NSC Vehicle-Stressed PB-NSC PB-Stressed 
IL-1α 100.0 ± 13.5 196.4 ± 24.3* 218.2 ± 39.7* 88.1 ± 19.6 
IL-1β 100.0 ± 15.2 207.4 ± 34.8* 249.1 ± 49.0* 72.8 ± 14.9 
IL-2 100.0 ± 15.3 163.6 ± 23.2* 173.9 ± 32.0* 63.3 ± 14.2 
IL-4 100.0 ± 18.4 143.9 ± 22.6 125.8 ± 29.5 96.7 ± 3.3 
IL-5 100.0 ± 15.4 192.0 ± 20.7* 209.3 ± 32.1* 83.4 ± 15.7 
IL-6 100.0 ± 9.5 293.8 ± 85.4 493.8 ± 134.2* 124.5 ± 35.8 
IL-10 100.0 ± 14.2 202.9 ± 38.3* 267.1 ± 59.8* 80.2 ± 17.0 
IL-12 100.0 ± 21.3 238.9 ± 49.1* 284.0 ± 69.6* 72.3 ± 19.6 
IL-13 100.0 ± 23.5 356.7 ± 82.5* 487.9 ± 122.6* 131.9 ± 40.8 
TNF-α 100.0 ± 16.0 203.6 ± 49.9 265.6 ± 67.5* 91.3 ± 15.1 
IFN-γ 100.0 ± 19.6 249.6 ± 48.9* 346.7 ± 84.5* 120.9 ± 33.3 
GM-CSF 100.0 ± 22.2 261.8 ± 45.2* 303.6 ± 72.3* 87.3 ± 23.5 
* values are significantly different from Vehicle-NSC 
Table 2.2 Cytokine Levels at Ten Days Post Treatment as a Percent of Vehicle--NSC 
Cytokine Vehicle-NSC Vehicle-Stressed PB-NSC PB-Stressed 
IL-1α 100.0 ± 7.9 99.3 ± 14.7 100.3 ± 8.0 94.2 ± 5.2 
IL-1β 100.0 ± 10.1 94.0 ± 17.6 97.8 ± 10.2 94.9 ± 8.3 
IL-2 100.0 ± 8.0 94.1 ± 13.7 93.8 ± 6.0 95.6 ± 5.1 
IL-4 100.0 ± 12.2 94.3 ± 21.4 96.9 ± 9.9 91.9 ± 8.5 
IL-5 100.0 ± 5.7 91.7 ± 11.5 95.3 ± 4.9 91.7 ± 4.9 
IL-6 100.0 ± 11.4 101.6 ± 18.8 105.4 ± 10.5 91.0 ± 8.6 
IL-10 100.0 ± 7.1 95.5 ± 12.0 94.4 ± 8.4 95.5 ± 5.3 
IL-12 100.0 ± 9.9 94.1 ± 18.3 95.4 ± 9.6 91.5 ± 6.4 
IL-13 100.0 ± 8.7 92.1 ± 17.0 95.8 ± 9.3 91.2 ± 7.3 
TNF-α 100.0 ± 12.9 99.0 ± 20.3 104.3 ± 12.6 95.3 ± 9.9 
IFN-γ 100.0 ± 12.6 99.0 ± 20.6 99.1 ± 11.8 84.1 ± 11.3 
GM-CSF 100.0 ± 12.4 91.6 ± 18.3 92.6 ± 9.3 94.2 ± 6.8 
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Table 2.3 Cytokine Levels at Three Months Post Treatment as a Percent of Vehicle--NSC 
Cytokine Vehicle-NSC Vehicle-Stressed PB-NSC PB-Stressed 
IL-1α 100.0 ± 14.3 85.9 ± 10.3 61.8 ± 9.2* 95.8 ± 14.6 
IL-1β 100.0 ± 17.5 83.5 ± 10.8 60.0 ± 10.7 82.7 ± 11.8 
IL-2 100.0 ± 13.6 79.7 ± 2.7 60.5 ± 10.2* 80.5 ± 8.4 
IL-4 100.0 ± 16.1 77.3 ± 5.2 58.2 ± 11.5* 84.3 ± 11.0 
IL-5 100.0 ± 8.0 90.9 ± 4.7 79.2 ± 6.5 95.1 ± 8.1 
IL-6 100.0 ± 14.0 87.8 ± 10.0 56.5 ± 10.0* 96.0 ± 14.2 
IL-10 100.0 ± 12.9 76.3 ± 3.7# 70.0 ± 8.6# 97.7 ± 14.5 
IL-12 100.0 ± 16.4 79.6 ± 9.5 60.1 ± 11.5* 89.2 ± 13.4 
IL-13 100.0 ± 16.0 83.9 ± 10.5 61.8 ± 10.2 81.6 ± 11.3 
TNF-α 100.0 ± 17.5 75.0 ± 10.3 55.2 ± 10.1* 68.4 ± 7.0* 
IFN-γ 100.0 ± 15.3 88.1 ± 11.5 59.0 ± 9.8* 99.0 ± 16.3 
GM-CSF 100.0 ± 14.3 78.3 ± 9.9 63.4 ± 11.2 85.3 ± 15.4 
* values are significantly different from Vehicle-NSC; # significant cross-over interaction 
 
2.3 DISCUSSION 
 This study supports two important conclusions: 1) time is a crucial factor to 
consider when regarding physiological and behavioral effects in response to stress and 
PB, and 2) the peripheral physiological effects and behavioral effects do not always 
progress in parallel. By detailing the etiology of these effects over time in a rodent 
model of Gulf War Illness, these data provide critical insight as to how stress and PB may 
have interacted to produce some of the well-characterized physiological and behavioral 
symptoms in veterans with GWI.  
PB Disrupts Homeostasis of Cholinergic Systems in GWI 
The acute effects of PB and stress on plasma cholinesterase and plasma 
corticosterone are both straightforward and consistent with clinical and preclinical 
literature. As a cholinesterase inhibitor, PB deceases cholinesterase activity when 
measured on the last day of drug treatment. Similarly, rats undergoing restraint stress 
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exhibit an increase in adrenal release of corticosterone levels relative to non-stressed 
rats. While there was no interaction between PB and stress at this time point, there was 
a selective interaction between PB and stress on both corticosterone and cholinesterase 
activity at the delayed time point. Only rats which received PB and were concurrently 
exposed to restraint stress demonstrated elevations in corticosterone and 
cholinesterase relative to controls three months following treatment-cessation. This 
provides important evidence that stress and PB interact to disrupt homeostasis of 
physiological systems and that these physiological changes emerge slowly over time.  
Although to our knowledge no human clinical study has directly assessed plasma 
AChE levels in GWI, BChE levels have been examined. Even though BChE is not the 
primary enzyme which metabolizes acetylcholine, individuals with a genotype for low-
functioning BChE are at a significantly greater risk for developing GWI if they were 
administered PB (Lea Steele, Lockridge, Gerkovich, Cook, & Sastre, 2015). However, 
there was no difference in BChE activity between veterans with GWI and veteran 
controls when collapsed across genotype. Given that our results determined that prior 
exposure to stress and PB increase cholinesterase over time, it is possible that this effect 
is driven by changes in AChE and not BChE. As AChE is the primary enzyme which 
metabolizes acetylcholine, changes in AChE activity would impact acetylcholine turnover 
in both the parasympathetic nervous system and neuromuscular junction (Macintosh, 
1941).  
Further studies will need to be performed to see if increases in plasma 
cholinesterase activity corresponds to increased or decreased acetylcholine levels in the 
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periphery, although it is tempting to speculate that increases in cholinesterase activity 
are associated with decreases in basal acetylcholine levels. Decreased acetylcholine 
levels paralleled by increased acetylcholine metabolism could explain some of the 
symptoms in GWI such as muscular fatigue and respiratory dysfunction. Despite 
muscular fatigue being a commonly reported symptom of GWI, clinical studies have 
struggled to find a direct link between changes in neuromuscular innervation and 
symptoms of muscular fatigue in GWI (Brown & Jason, 2007). However, these studies 
have relied primarily on physical grip strength or receptor expression. Cholinergic 
effects on muscular fatigue may be subtler and linked to the temporal dynamics 
associated with acetylcholine release and metabolism.  
As the cholinergic anti-inflammatory pathway of the vagus nerve also regulates 
the peripheral innate immune response, changes in cholinesterase activity would also 
impact regulation of inflammation. The innate immune response is the first of two arms 
of the immune system and provides a general defense against a broad range of general 
infectious organisms (e.g. LPS). In contrast, the adaptive immune response is a targeted 
and antibody driven defense managed by helper T-cells. Cytokines provide an important 
means of communication in both the innate and adaptive immune responses with some 
cytokines primarily associated with innate immunity (e.g. TNF-α) and others primarily 
associated with adaptive immunity (e.g. IL-4). Following stimulation of the vagus nerve, 
acetylcholine activates nicotinic receptors on macrophages which inhibit the release of 
TNF-α, thus regulating innate immunity (Bernik et al., 2002; Borovikova et al., 2000; H. 
Wang et al., 2003). As such, a PB-induced shift in the homeostasis of cholinergic 
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metabolism can have far-reaching consequences. One possible mechanism is that PB-
induced changes in cholinesterase activity disrupt TNF-α synthesis and release, thereby 
directly contributing to the chronic depression in basal levels of TNF-α at three months 
post-treatment. Although high levels of TNF-α are associated with a variety of disorders 
including depression and diabetes (Y. Liu, Ho, & Mak, 2012; McAfoose & Baune, 2009; 
Moller, 2000), low levels of TNF-α can also be detrimental as this can impair the body’s 
ability to respond effectively to infections. Interestingly, some studies have indicated 
higher levels of bacterial infections in soldiers returning from the Gulf War who develop 
GWI (Nicolson, Nicolson, & Nasralla, 1998; Nicolson & Nicolson, 1996). 
PB and Stress Interact to Increase Corticosterone in GWI 
Alterations of the HPA axis in veterans with GWI are well documented – 
including enhanced cortisol suppression to a dexamethasone challenge (Golier et al., 
2006) and elevations of cortisol relative to ACTH when compared to non-deployed 
controls (Golier et al., 2007). This shift in the ACTH:cortisol ratio was positively 
correlated with cognitive dysfunction in veterans. Our study indicates that PB and stress 
interact and may have caused some of the perturbations in cortisol levels evidenced in 
human clinical populations. These elevations of cortisol could contribute to some of the 
neurological changes in GWI which may in turn contribute to the cognitive dysfunction – 
particularly learning and memory impairments. Glucocorticoids easily cross the blood-
brain barrier, and as the hippocampus robustly expresses glucocorticoid receptors 
(Bruce S McEwen, Davis, Parsons, & Pfaff, 1979), chronic elevations of 
cortisol/corticosterone have profound effects on this brain region. Elevations of cortisol 
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in other diseases such as recurrent major depression (Bremner et al., 2000) and 
Cushing’s syndrome (Starkman, Gebarski, Berent, & Schteingart, 1992) are associated 
with decreases in hippocampal volume and function on learning and memory tests.  
In support of interactions between cholinesterase inhibitors and hippocampal 
volume, veterans with suspected exposure to low-doses of Sarin following the weapons 
demolition at Khamisiyah have significantly reduced gray matter and hippocampal 
volume relative to non-exposed veteran peers (Chao, Rothlind, Cardenas, Meyerhoff, & 
Weiner, 2010). This link between cholinesterase inhibition and hippocampal volume has 
also been supported by preclinical studies. Animal models exposed to a combination of 
PB, DEET and permethrin in combination with mild chronic stress over the course of 4 
weeks also exhibit reduced hippocampal volume along with decreases in neurogenesis 
and inflammation (Parihar et al., 2013). While our results provide evidence that PB in 
the absence of other chemical exposures is sufficient to contribute to endocrine 
disruption, future studies will need to verify if PB in combination with stress is also 
sufficient to produce chronic decreases in hippocampal volume. It is possible that the 
interactions between stress and PB on chronic corticosterone production contribute to 
many of the hippocampal changes evidenced in both clinical and preclinical studies. In 
summary, stress and PB interact over time to disrupt homeostasis of endocrine and 
cholinergic systems, providing insight into how these factors may have contributed to 
the pathogenesis of GWI.  
PB Suppresses the Immune Systems in GWI over Time 
 In the search for biomarkers for GWI, shifts in immune activation have been the 
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most extensively investigated over the last decade. There has been a focus as to 
whether veterans with GWI exhibit a Th1 or Th2 cytokine shift. Th1 cytokines are 
primarily associated with stimulating phagocytic responses through the innate immune 
system whereas Th2 cytokines tend to be associated with antibody production 
(Romagnani, 1999). The importance of a balance between Th1 and Th2 cytokines 
emerged in the late 1980s following studies demonstrating that T-helper cells can 
produce specific cytokine profiles with Th1-producing cells predominantly expressing 
mRNA for IL-2, IFN-γ, TNF and GM-CSF and Th2-producing cells predominantly 
expressing mRNA for IL-4 and IL-5 (Cherwinski, Schumacher, Brown, & Mosmann, 1987). 
The idea that an optimal balance of these cytokines is critical for normal immune 
function and imbalanced in disease states is one that has gathered considerable interest 
over the last few decades (Kidd, 2003). An exaggerated Th1 cytokine profile has 
predominated literature on rheumatoid arthritis, diabetes, and multiple sclerosis 
whereas an exaggerated Th2 cytokine profile has been associated with the development 
of allergies and asthma, although some inconsistency within the literature has 
suggested the issue is more complicated than a binary division suggests (Kidd, 2003). 
Regardless, a core principle of immune system is that an appropriate immune response 
is not necessarily the largest or the most cytokine-specific, but rather one that succinctly 
and effectively responds to and then terminates the infectious cycle.  
For Gulf War Illness, an early hypothesis which emerged was that veterans with 
GWI exhibit a shift towards a Th2 cytokine profile (Rook & Zumla, 1997). This hypothesis 
was driven primarily by 1) similarities in symptoms of GWI with chronic fatigue 
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syndrome, which has evidence of a dominant Th2 cytokine profile (Skowera, Cleare, et 
al., 2004), and 2) the impact of stress-induced increases in cortisol on cytokine 
expression. However, support for this cytokine profile in the GWI literature is 
inconsistent. One clinical study testing this hypothesis failed to find a Th2 dominant 
profile in GWI (Skowera, Hotopf, et al., 2004). Another study partially supported it, 
suggesting that the most important cytokines for distinguishing GWI from diseases with 
similar symptoms are IL-7, IL-4, TNF-α, IL-13, and IL-17F (Khaiboullina et al., 2015). In 
this study, IL-4 and TNF- α were down-regulated in GWI relative to controls. Our study 
supports this finding as PB decreased both IL-4 and TNF-α chronically. However, due to 
the heterogeneity of the illness, it is likely that different populations of veterans with 
GWI present different cytokine profiles and that the presentation of these cytokine 
profiles is driven by different exposures. For example, veterans in combat zones who 
took PB may be more prone to changes in IL-4 and TNF-α whereas veterans who were 
exposed to low levels of nerve gas following the demolition of Khamisiyah or served off-
shore in the Navy may exhibit different cytokine profiles, thus contributing to the 
variability of cytokine profiles evidenced in clinical studies of GWI. It is also possible that 
as the veterans continue to age, their cytokine profile is continuing to evolve, or that 
their current situational context is continuing to evolve and further influencing their 
cytokine profiles. The challenge, then, is to determine which exposures influence which 
cytokine profiles in veterans, and how these profiles change over time.  
Our study demonstrated that PB significantly impacts cytokine profiles over time. 
Acutely, PB exhibits a dramatic inflammatory effect. This effect was surprising given the 
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interactions of cholinesterase inhibitors at cholinergic terminals in the parasympathetic 
nervous system, but it could be that chronic administration of a drug which disrupts the 
parasympathetic nervous system may lead to increases in inflammation. Future studies 
would need to determine if PB also exhibits this pro-inflammatory effect on the first day 
of treatment. In our study, PB did exhibit anti-inflammatory properties, but only in the 
presence of another pro-inflammatory event such as chronic stress. Three months later, 
rats with a prior history of PB demonstrate a depressed cytokine profile with significant 
decreases in IL-2, IL-4, IL-6, IL-10, and TNF- α under non-stimulated conditions, 
suggesting that combinations of PB and stress can differentially disrupt homeostasis of 
the immune system. This downregulation of IL-4 and TNF-α is important as it parallels 
findings in clinical studies by Khaiboullina et al. (2015) as well as other preclinical models 
where combinations of restraint stress, PB, and various pesticides saw a reduction in the 
expression of IL-4 and IL-10 in the hippocampus six months following the cessation of 
treatment (Shetty et al., 2017). As such, while we measured levels of peripheral 
cytokines, this PB-induced suppression of cytokine levels may also be evident in the 
brain. Future studies will need to confirm this. 
Under normal regulatory conditions, increases in IL-4 expression can provide 
feedback to attenuate the TNF-α response, but our model suggests that both IL-4 and 
TNF-α are suppressed several months after PB treatment. This could suggest that PB 
dysregulates homeostasis of the immune system by potentially disrupting negative-
feedback signals, rendering it ill-prepared to respond appropriately to threats. Clinical 
data support this hypothesis as veterans with GWI exhibit an impaired coordination of 
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the Th1 and Th2 immune response following an exercise challenge which stimulates a 
mild inflammatory response (Broderick et al., 2011, 2013). Other studies have confirmed 
these findings, indicating that male veterans with GWI can be differentiated from 
healthy males based on their cytokine profiles at rest and following recovery from an 
exercise challenge, but not during the peak of the challenge (Smylie et al., 2013). This 
suggests that it is the ability of the immune system to recover from the challenge and 
not the peak immune response which is impaired in veterans with GWI. Although the 
cytokine profiles in the current study were under non-stimulated conditions, future 
studies should examine whether PB and stress produce similar deficits in the Th1: Th2 
coordinated response to a state of challenge, either using a mild dose of LPS or in 
response to exercise. In addition, although our study did not examine females, clinical 
studies have suggested that under basal conditions, there are no sex differences in 
veterans with GWI (Smylie et al., 2013). However, there are sex differences when placed 
under an exercise challenge. As such, future preclinical studies should verify if PB 
differentially impacts males and females in response to a challenge.  
Reduced levels of IL-4 and TNF-α may also contribute to some of the clinical 
symptoms which characterize GWI. Low levels of IL-4 are significantly correlated to 
chronic pain in some clinical studies (Üçeyler et al., 2006), and preclinical studies have 
shown that administration of IL-4 decreases hyperalgesia evoked by painful stimuli 
(Cunha, Poole, Lorenzetti, Veiga, & Ferreira, 1999). However, understanding the 
intricacies of cytokine-cytokine interactions, coordination of appropriate immune 
responses, and associated physiological symptoms is extremely complex as these 
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systems act in concert, not in isolation. Further clinical and preclinical studies are 
necessary to elaborate on these emerging findings.  
PB Exacerbates Stress-Induced Short-Term Deficits in Contextual Fear Conditioning 
Although veterans with GWI exhibit a host a host of memory problems which 
have persisted over several decades, our model demonstrated only transient deficits in 
contextual fear conditioning following PB and stress. One week following the cessation 
of treatment, rats with a prior history of restraint stress exhibited deficits in contextual-
fear conditioning, and this effect was exacerbated by PB, suggesting that PB and stress 
interact to impair fear memory. The hippocampus is critically involved in contextual fear 
conditioning, and rats with hippocampal lesions show severe deficits in the acquisition 
(Phillips & LeDoux, 1992) as well as the recall of contextual fear memory if the 
hippocampus is lesioned shortly after conditioning (J. J. Kim & Jung, 2006). One possible 
mechanism is that elevations in corticosterone at this time point contributed to this 
memory deficit. Although whether corticosterone facilitates or impairs context-learning 
depends on surrounding conditions, some studies have suggested that long-term-
depression/long-term-facilitation (LTD/LTP) of memories is dependent on the relative 
occupancy of minerocorticoid (MR) and glucocorticoid receptors (GR) (de Kloet, Oitzl, & 
Joëls, 1999). Elevations in basal corticosterone in rats with a previous stress history may 
have tipped this balance during fear conditioning, contributing to an impairment in 
contextual fear learning as evidenced by decreases in freezing behavior.  
Another possibility is that shifts in immune function in PB-treated rats are 
contributing to some of the deficits in contextual fear memory. Cytokines are important 
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facilitators of normal cognitive function (McAfoose & Baune, 2009), and TNF-α in 
particular plays an important role in the strength and permanence of LTP in the 
hippocampus (Beattie et al., 2002). If brain levels of TNF-α parallel the chronic decreases 
in peripheral TNF-α, then this could partially explain why PB-stress rats fail to show the 
same increases in contextual-freezing as vehicle-stressed rats at three-months post-
treatment. However, it is important to note that we did not measure cytokines 
immediately following fear conditioning. As PB and stress could further exacerbate 
disruptions in cytokine signaling following a stressful challenge, measuring the cytokine 
response directly following fear conditioning or another memory-test would be an 
important future study.  
These impairments in fear conditioning following combinations of PB and stress 
one week after the end of treatment have important clinical implications, particularly 
regarding PTSD rates in Gulf War veterans. PTSD is undoubtedly a prevalent condition in 
veterans from the Gulf War with higher rates in deployed versus non-deployed veterans 
(Ikin et al., 2004; Perconte, Wilson, Pontius, Dietrick, & Spiro, 1993). However, when 
Gulf War veterans are compared with other actively deployed veterans, prevalence of 
PTSD is reduced, suggesting that stress from active deployment may be a greater risk 
factor for PTSD than specific Gulf War conditions (Ikin et al., 2004).  
Another important consideration is that the prevalence of PTSD in Gulf War 
veterans changes over time. Immediately following the Gulf War, several studies 
suggested low rates of PTSD with estimates between 2% and 6% (Perconte et al., 1993; 
Wolfe, Erickson, Sharkansky, King, & King, 1999). Two years after the war, PTSD rates 
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doubled (Wolfe et al., 1999). Similarly, in the current study, we saw an increased risk for 
contextual fear conditioning three months following the cessation of treatment 
selectively in rats which were stressed but did not receive PB. This suggests that 
repeated psychological stress may exert some latent effects on fear conditioning, 
possibly explaining in part some of the increases in prevalence in PTSD in the years 
following the return from war. Rates of conditioned freezing were not increased in the 
PB-stressed rats or PB-non-stressed rats relative to vehicle-NSC rats, suggesting that PB 
in the presence of stress may mitigate this latent effect on fear conditioning. 
Alternatively, these data could indicate that continued post-deployment stress or 
infection are crucial factors mediating the progression of GWI.  
Corticosterone levels were also increased selectively in the PB-stressed rats at 
this time point. Either 1) corticosterone differentially contributes to fear conditioning at 
these time points, or 2) by the delayed time point the homeostatic balance between 
multiple systems have been sufficiently disrupted to complicate these interactions. 
However, veterans returning from the Gulf War did not return to stress-free conditions. 
Therefore, an important consideration is whether intermittent recurring stressors 
during that three-month post-treatment stretch would have exacerbated effects in PB 
conditions.  
Conclusions 
In sum, this study provides evidence that combinations of PB and stress 
contribute to the development of various physiological and psychological symptoms 
evidenced in veterans with GWI, and that the development of these symptoms change 
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over time. Corticosterone levels, like cytokines and cholinesterase activity, exhibit a 
homeostatic shift over time following chronic stress and PB. In addition, PB and stress 
interact to impair fear conditioning ten days following the cessation of treatment, 
providing further support that combinations of PB and stress impair memory networks. 
A history of stress increases fear conditioning at the delayed time point, but only in the 
absence of PB. This suggests that while stress may increase some PTSD-like symptoms, 
PB mitigates this effect.  
As soldiers were exposed to a variety of factors, it is likely that the motley of 
physiological changes contributes to a range of these symptoms. Further studies will be 
needed to investigate whether PB and stress-induced changes in peripheral cytokines 
and cholinesterase contribute to chronic pain and muscular fatigue as opposed to 
cognitive dysfunction. Examining the progression of these symptoms over time is critical 
as evidence continues to mount that severity and prevalence of GWI symptomology is 
likewise progressing over the last several decades
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CHAPTER 3 
EXPERIMENT TWO: ACETYLCHOLINE IN GULF WAR ILLNESS  
Veterans with GWI exhibit a host of central nervous system deficits, including 
chronic headaches, depression, anxiety, sleep disturbances, chronic pain, attentional 
deficits, and working and long-term memory impairments (Haley et al., 1997; Steele et 
al., 2012; Sullivan et al., 2003; White et al., 2016). When paired with the peripheral 
deficits also evidenced by these veterans – including respiratory problems, rashes, 
chronic diarrhea, and muscular fatigue – there is a strong parallel to symptoms 
documented in cases of cholinergic toxicity (Pope et al., 2005). This correlation supports 
a plethora of epidemiological and preclinical studies suggesting that PB contributed to 
both peripheral and central symptoms in this population of veterans (Parihar et al., 
2013; L Steele et al., 2012; Lea Steele et al., 2015; Sullivan et al., 2003).  
Whether PB impacts the central cholinergic system is highly controversial. Some 
studies reported that chronic stress exposure creates a “leaky” blood-brain barrier 
(Friedman et al., 1996), allowing PB to cross and directly impact central cholinergic 
function, but other studies failed to replicate this finding (Amourette et al., 2009; Grauer 
et al., 2000; Kant et al., 2001; Song et al., 2002; Tian et al., 2002). To address whether 
stress and PB interact to either directly or indirectly influence central cholinergic 
function, the current study used a rodent model of GWI in combination with in vivo 
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microdialysis to examine the neurochemical response to an immune challenge and an 
acute stress challenge. Acetylcholine levels were assessed in two brain regions: the PFC 
and the hippocampus. These brain regions were targeted due to their robust cholinergic 
innervation and critical contribution to cognitive processes which exhibit deficits in 
veterans with GWI (Fadel, 2011; Lange et al., 2001; Mesulam, Mufson, Wainer, & Levey, 
1983).  
An immune challenge was selected as some clinical studies have suggested that 
adverse responses to bacterial infections may be an important component instigating 
the progression of GWI (Nicolson et al., 1998; Nicolson & Nicolson, 1998). In addition, 
clinical studies have suggested that veterans with GWI exhibit aberrant immune 
function, particularly in response to a challenge (e.g. exercise) (Broderick et al., 2013; 
Whistler et al., 2009). This finding has been corroborated with preclinical models which 
have suggested that immune function in the peripheral and central nervous system may 
be altered in models of GWI (Shetty et al., 2017; Whistler et al., 2009). In contrast, a 
restraint stress challenge was selected to assess neurochemical shifts to psychological 
stressors as veterans experienced many recurrent psychological post-deployment 
stressors. Altered reactions to systemic infection and psychological stress following the 
unique conditions in theater may influence the chronic progression of GWI symptoms. 
We tested the hypothesis that combinations of PB and stress alter the 
cholinergic response to an innate immune challenge, thus potentially contributing to the 
cognitive deficits evidenced in veterans with GWI. In addition, we tested whether an 
acute psychological stressor (restraint stress) produced similar deficits in the cholinergic 
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response in rats with a prior history of PB and repeated stress. Although PB is not 
hypothesized to impact basal levels of cholinergic function, PB is hypothesized to 
interact with stress to produce deficits in the cholinergic response in the PFC and 
hippocampus.  
 
3.1 METHODS AND MATERIALS 
As in Experiment One, young adult Sprague Dawley rats were acclimated to 
housing conditions for one week following transport, prior to the onset of experiments. 
After a week, rats in the pilot study underwent surgery for in vivo microdialysis. Rats in 
the GWI study went through the GWI paradigm as previously described in Chapter 1 
(Figure 1.2). 
In vivo microdialysis was performed to assess how PB and stress interacted to 
influence how the PFC and hippocampus responded to both (a) an LPS challenge and (b) 
a restraint stress session. However, in order to determine the optimal dose of LPS for 
the GWI animals, a pilot study was first performed to assess 0 µg/kg, 10 µg /kg, 30 µg 
/kg, 100 µg /kg, and 300 µg /kg LPS impacted acetylcholine in the PFC and hippocampus.  
Surgical Procedures 
All rats underwent stereotaxic surgery to unilaterally implant two guide cannulae 
into the PFC and dorsal hippocampus for in vivo microdialysis. Each rat was induced with 
5% isoflurane and 1.5 L/min oxygen, after which 2% isoflurane was used for anesthesia 
maintenance. The rat’s head was shaved and scrubbed with alternating betadine and 
alcohol wipes, following which each rat received three pericranial injections of 0.05 mL 
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carbocaine, a local anesthetic. A scalpel was then used to make a midline incision down 
the skull. Sterile q-tips were used to remove the fascia and connective tissue, and 
bregma was located and marked. Target coordinates were marked relative to bregma, 
and holes for the guide cannulae and anchoring screws were marked and drilled with a 
Dremel tool. BASi interlocking intracerebral guide cannula and stylet (MD-2251) were 
placed at the following coordinates (Table 3.1) and secured with Lang Ortho-Jet fast-
drying orthodontic acrylic resin: 
Table 3.1. Stereotaxic Coordinates for Guide Cannulae 
Coordinates relative to Bregma PFC Hippocampus 
Anterior-Posterior (AP) +3.0 mm -5.2 mm 
Lateral (L) ±0.5 mm ±3.8 mm 
Dorsoventral (DV) -2.5 mm -3.6 mm 
Angle 0 % 10 % 
Coordinates for the guide cannulae were selected based on the Paxinos and Watson rat 
brain atlas (1998). Left and right hemispheres were counterbalanced across rats. Post-
operatively, each rat received a 0.5 mg/kg subcutaneous injection of buprenorphine and 
was then allowed to recover in his home cage with bacon softies for forty-eight hours 
prior to habituation for microdialysis procedures.  
In Vivo Microdialysis 
 Two days after surgery, rats began habituation for in vivo microdialysis. The 
microdialysis room was kept under low lighting conditions (50 lux) with continuous 
white noise. In the center of the microdialysis room is the Raturn™ apparatus. The 
Raturn™ apparatus is a movement-sensitive apparatus which consists of four round-
bottomed bowls on rotating plates, which critically maintains the integrity of the 
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microdialysis lines while enabling the rat to move freely at will. Each rat was provided 
his own bowl with fresh bedding at the onset of the first day of habituation. Dividers 
separated each bowl so that each rat was visually separated from the next. Rats were 
habituated to the microdialysis apparatus for four days and a total of 20 hours. Starting 
on the second day of habituation, each rat was provided a collar and tethered to the 
Raturn™ system, allowing the animal to freely move around the bowl as it gently 
counter-rotated in response. On the day of microdialysis, animals were brought up to 
the microdialysis room shortly after lights-on (7:00 AM). 2 mm probes from BASi (MD-
2200) were flushed for thirty minutes with a 0.005% proclin solution to eliminate the 
glycerol coating, followed by infusion with a solution of artificial cerebral spinal fluid 
(aCSF) and 100 nM neostigmine. aCSF simulates the natural ionic composition of the 
brain and contains the following: 150 mM NaCl, 3 mM KCl, 1.7 mM CaCl2H2O, 0.183 mM 
MgCl26H2O, 5 mM D-glucose. The addition of the neostigmine to the aCSF solution is 
critical as collection of in vivo extracellular acetylcholine levels approximate the 
detection limit of high performance liquid chromatography (HPLC) machines (Chang, 
Savage, & Gold, 2006). Neostigmine prevents the rapid enzymatic degradation of 
acetylcholine by cholinesterases, thus boosting collectible levels of acetylcholine.   
The probe was then inserted into guide cannula in the PFC and hippocampus in 
place of the stylets. Probes were infused with the neostigmine/aCSF solution at a rate of 
2 µL/min. The probe consists of a semi-permeable membrane with a 30 kDa molecular 
weight cutoff which extends 2 mm beyond the tip of the guide cannula. This membrane 
allows the free passage of small-molecule neurotransmitters in the absence of larger 
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molecules such as neuropeptides or hormones. Because the probe extends beyond the 
guide cannula, three hours following the insertion of the probe are collected as discard. 
Discard collection began at approximately 9:00 AM each dialysis day. This period is 
critical for equilibration of the extracellular milieu following probe damage.  
Sample collection began at noon, following the discard period. Samples were 
collected in 15 minute intervals, yielding 30 µL of dialysis per collection, and 
immediately stored at -80oC until analysis. Four collections were taken prior to any 
stimulus presentation to assess basal neurotransmitter levels. After the cessation of one 
microdialysis session, rats had a 48-hour recovery period before the following session to 
enable the restoration of any depleted neurotransmitters. No animal went through 
more than two microdialysis sessions.  
Pilot study: in vivo microdialysis with LPS challenge 
 Prior to the start of the GWI studies, a pilot study was performed to assess the 
dose-response effect of an intraperitoneal injection of LPS on acetylcholine levels in the 
PFC and hippocampus. Each microdialysis session consisted of a total of sixteen 
collections: four baseline collections, followed by an intraperitoneal injection of LPS and 
12 post-injection collections. During each session, rats received one of the following 
doses of LPS in a counter-balanced design: 0, 10, 30, 100, or 300 µg/kg LPS. LPS was 
diluted daily immediately prior to use from 1 mg/mL frozen stock solution in sterile 
saline. After the second microdialysis session, rats were anesthetized with isoflurane 
and intracardially perfused with 100 mL of 0.1 M PBS followed by 300 mL of 4% 
paraformaldehyde in 0.1M PB. Brains were removed and placed in a 30% sucrose/0.1 M 
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PB solution at 4oC where they were allowed to sink over several days. After sinking, 
brains were rapidly frozen using isopentane on dry ice and stored at -80oC. A sliding 
microtome was then used to cut 40 µm sections to verify probe placement in each rat.  
For this pilot study, in the PFC, the LPS significantly increased acetylcholine levels 
in a dose-response manner, F(4, 15)=3.48, p =.03. Specifically, both 30 and 100 µg/kg 
LPS increased acetylcholine levels relative to rats injected with vehicle, p = .04 and p = 
.01 respectively. An injection of 300 µg/kg LPS resulted in a 16% greater increase in 
acetylcholine relative to an injection of 30 µg/kg LPS, although the two doses were not 
statistically significantly different from one another, p = 0.29. In the hippocampus, there 
is a non-significant trend for LPS dose to impact acetylcholine levels, F(1, 4)=2.36, p = 
0.09, as well as a trend for a dose × time interaction, F(60, 270)=1.37, p = 0.05. While 30 
µg/kg LPS did increase acetylcholine levels in the hippocampus, there did not appear to 
be larger response with increasing the dose beyond this amount. Based off these 
parameters, 30 µg/kg LPS was selected for the following GWI studies as 1) it increased 
acetylcholine levels in both the PFC and hippocampus, and 2) in the PFC, 30 µg/kg LPS 
exhibited a sub-maximal effect on acetylcholine levels. 
GWI: in vivo microdialysis with LPS challenge 
 The LPS challenge in the GWI rats was performed on the first of two 
microdialysis days (Figure 3.1). This session consisted of four baseline collections, 
followed by an intraperitoneal injection of 30 µg/kg LPS. This dose of LPS was selected 
based on data from pilot studies to yield a significant but sub-maximal increase in 
acetylcholine. As with the pilot study, 12 collections followed the injection of LPS,   
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Figure 3.1. Dose-response of LPS on Acetylcholine in the PFC and Hippocampus. 
One of five different doses of LPS (0, 10, 30, 100, 300 µg/kg) was administered 
immediately prior to the fifth collection. Panel A. LPS exhibited a dose-response 
effect on acetylcholine levels in the PFC with 300 µg/kg producing the largest effect. 
As 30 µg/kg increased acetylcholine levels beyond saline injections in the PFC while 
still being sub-maximal to the 300 µg/kg. As such, 30 µg/kg LPS was used for all 
subsequent experiments. Panel B. Although LPS also increased acetylcholine in the 
hippocampus, a dose-response effect was not discernible.  
LPS 
LPS 
A. 
B. 
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making a total of 16×30 µL collections. Immediately after the end of the last 
microdialysis collection, rats were returned to their home cage and their tails were bled. 
Blood was collected on ice in a microcentrifuge tube and then spun down in a 
microcentrifuge at 4oC for 15 minutes × 30,000 g. The supernatant (plasma) was 
removed and stored at -80oC for later analysis.  
GWI: in vivo microdialysis with acute restraint challenge and tissue collection 
 The acute restraint challenge was performed on the second day of microdialysis, 
48 hours following the LPS challenge (Figure 3.2). This session consisted of four baseline 
collections followed by four collections of restraint stress and then four collections 
following the release from restraint. For restraint, rats were returned to their home 
cages and secured in plastic restrainers specifically designed to not interfere with the 
microdialysis tubing. Rats went into restrainers at approximately 1:00 PM and were 
released from restrainers at 2:00 PM. When rats were released from the restrainers, 
they were returned to the microdialysis bowls. While this restraint challenge exhibits 
similar psychological parameters to the repeated restraint stress in the GWI paradigm, 
there are several notable differences: 1) the timing of the onset of restraint stress is 
shifted, 2) the room in which restraint stress occurred is different, and 2) the plastic 
restrainers are physically unique from the wire mesh restrainers. Therefore, while some 
aspects of this restraint challenge may be considered parallel to previous restraint 
conditions (homotypic stress), others are unique (heterotypic stress). 
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Figure 3.2. Timeline for Experiment Two. All rats underwent the GWI paradigm of ± 
drug treatment and ± repeated restraint stress. The day following the end of the 
treatment paradigm, rats were prepared for surgery where a guide cannula was 
unilaterally implanted into the prefrontal cortex and hippocampus. After two 
recovery days, rats began habituation to the microdialysis chamber. Rats were 
habituated for four days and a total of twenty hours. The first microdialysis session 
was performed on Day 22 where each rat received a 30 μg/kg injection of LPS. Tail 
bleeds were performed immediately following the end of the session. Forty-eight 
hours later, rats were returned to the microdialysis chamber for a restraint stress 
challenge. Rats were euthanized immediately following the end of the second 
microdialysis session, at approximately 4:00 PM on Day 24. 
Day 24 
Day 22 
Day 5 Day 1 
± Repeated Restraint 
± PB Treatment 
Day 14 
Microdialysis: 
30 µg/kg LPS 
 
Microdialysis: 
1 hour restraint 
challenge & 
Euthanasia 
Day 15 
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High Performance Liquid Chromatography: Acetylcholine 
 In random order from sample collection, 20 µL of previously frozen 
microdialysate sample was loaded onto an EiCom AC-GEL reverse-phase analytical 
column, packed with a polymer resin, where choline and acetylcholine were isolated 
from other biogenic compounds in interaction with a mobile phase consisting of 50 mM 
potassium bicarbonate, 300 mg/L sodium decanesulfonate, and 50 mg/mL 2Na EDTA, 
pH 8.4. Afterwards, a dual enzymatic column AC-ENZYM II from Eicom first metabolized 
acetylcholine into choline and acetyl-CoA by AChE, and then choline was further 
metabolized into hydrogen peroxide by choline oxidase. The hydrogen peroxide was 
oxidized at the platinum electrochemical detector with an applied current of +450 mV, 
resulting in O2, 2H+, and 2e. The potential was read using the EiCom HT-500 detector 
system. Concentration of acetylcholine in samples was interpolated against a three-
point standard curve of 2, 0.4, and 0.1 pmol/20 μL acetylcholine. 
Euthanasia 
After the second microdialysis session, rats were immediately anesthetized with 
isoflurane and transcardially perfused with 100 mL of 0.1 M PBS followed by 300 mL of 
4% paraformaldehyde in 0.1M PB. Brains were removed and placed in a 30% 
sucrose/0.1 M PB solution at 4oC where they were allowed to sink over several days. 
After sinking, brains were rapidly frozen using isopentane on dry ice and stored at -80oC. 
A sliding microtome was then used to cut 40 µm sections to verify probe placement in 
each rat. 
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At the start of the perfusion, trunk blood was collected from the right atrium and 
kept on ice. Blood was spun down in a microcentrifuge at 4oC for 15 minutes × 30,000 g. 
The plasma supernatant was aspirated and stored in centrifuge tubes at -80oC for later 
analysis. 
Statistical Analyses 
Results were calculated as a 2×2×16 mixed ANOVA for the LPS session and a 
2×2×12 mixed ANOVA for the restraint challenge session. For between subjects, this 
experiment had 2 levels of drug treatment (vehicle, PB), 2 levels of stress (NSC, 
stressed). Within-subjects repeated measures consisted of 16 levels, representing the 16 
consecutive collections during microdialysis for the LPS challenge. The restraint stress 
challenge had a total of 12 collections: 4 baseline, 4 during restraint, 4 post-restraint. 
Following significant interactions, simple main effects post hoc tests were performed 
with Bonferroni post-hoc corrections for family-wise error.  
Power analyses for in vivo microdialysis were performed a priori with an effect 
size of 0.8 and α=0.05; analyses suggested that a sample size of n=8 per group with a 
total N = 32 would be sufficient for achieving statistical significance. After correcting for 
statistical outliers and other complications during microdialysis and HPLC (e.g. erratic 
baseline, undetectable analytes, loss of cannula, broken probe), actual sample size for 
each condition was as follows: 
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Table 3.2 Sample Size for Each Condition in GWI Paradigm 
 PFC Hippocampus 
 LPS Restraint LPS Restraint 
Vehicle-NSC 8 5 9 7 
PB-NSC 10 9 8 6 
Vehicle-Stressed 6 6 6 5 
PB-Stressed 7 7 8 6 
 
3.2 RESULTS 
GWI In Vivo Microdialysis: Acetylcholine  
Basal Levels of Acetylcholine 
On the first day of microdialysis, prior to the LPS challenge, there was no effect 
of either a prior history of PB or restraint stress on basal acetylcholine levels in the PFC, 
F(1, 25) = 0.25, p = 0.62, or hippocampus, F(1, 27) = 2.37, p = 0.13 (Figure 3.3). On the 
second day of microdialysis, prior to the restraint challenge, the PFC still did not exhibit 
any differences in basal acetylcholine levels between any groups, F(1, 22) = 0.53, p = 
0.48. However, on the second day of microdialysis, there was a significant cross-over 
interaction between PB and stress in the hippocampus, F(1, 21) = 12.32, p = 0.002 (Table 
3.3). In this cross-over interaction, acetylcholine was elevated in PB-NSC and vehicle-
stressed rats relative to vehicle-NSC and PB-stressed counterparts. This shift in basal 
acetylcholine levels in the hippocampal on the second day of microdialysis is difficult to 
interpret as it could be a function of several factors including differential recovery from 
probe damage, residual effects of LPS, or self-selection as the second day of 
microdialysis had a lower n-size due to experimental complications (e.g. probe 
breaking). 
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Figure 3.3. Basal Levels of Acetylcholine. On the first day of 
microdialysis, prior to the LPS challenge, there was no effect of 
either PB or stress on basal acetylcholine levels in the PFC (Panel 
A) or hippocampus (Panel B). This suggests that neither a history 
of PB nor restraint stress either independently or in interaction 
impact affect basal acetylcholine levels in either brain region. 
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Table 3.3 Basal Acetylcholine Levels on Day Two of Microdialysis  
 PFC Hippocampus 
Vehicle-NSC 0.09 ± 0.03 0.07 ± 0.01 
PB-NSC 0.14 ± 0.02 0.14 ± 0.02* 
Vehicle-Stressed 0.10 ± 0.03 0.14 ± 0.03* 
PB-Stressed 0.09 ± 0.02 0.07± 0.02 
*significant cross-over interaction, p = 0.002; Data expressed as mean ±SEM (p mol/20 
μL) 
 
LPS challenge 
LPS significantly increased acetylcholine levels in the PFC over time in all rats, 
F(15, 405) = 12.0, p < 0.001 (Figure 3.4). However, there was also a main effect of stress 
where a prior stress history attenuated the cholinergic response to LPS in the PFC, F(1, 
27) = 6.52, p = 0.017. Additionally, there was a stress by time interaction, F(15, 405) = 
1.79, p =0.034. Specifically, while LPS increased acetylcholine relative to baseline at 
every collection starting at collection 5, prior stress history attenuated this effect 
relative to NSC rats at collections 5 and 6, (p = 0.004 and 0.009, respectively). There was 
no effect of PB on acetylcholine levels in response to an LPS challenge in the PFC, 
suggesting that 1) while prior stress history attenuates the cholinergic response to an 
immune challenge suggesting cross-over between these two heterotypic events, 2) 
stress and PB do not interact to influence the prefrontal cortical cholinergic response to 
an immune challenge.  
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Figure 3.4. Cholinergic Response to an LPS Challenge in the PFC. In rats without a 
prior restraint stress history, LPS increased acetylcholine levels over time with peak 
increases at collection 5 and a secondary, gradual increase starting an hour after the 
injection. In rats with a prior restraint stress history, the cholinergic response to LPS 
was significantly blunted relative to vehicle-NSC rats at collections 5 and 6, p < 0.05.  
*: effect of stress relative to NSC rats 
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Figure 3.5. Cholinergic Response to an LPS Challenge in the Hippocampus. Although 
LPS increased acetylcholine levels in the hippocampus in vehicle-NSC rats, either a 
prior history of PB or a prior history of stress attenuated this effect between 
collections 11-14. Rats which received PB but had no prior restraint stress history had 
a similar, attenuated cholinergic response to LPS as did rats with a prior restraint 
stress history. This suggests that the hippocampus is particularly sensitive to the 
cholinergic effects of PB in the context of an immune challenge. 
*: significant effect of PB in NSC rats 
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In the hippocampus, there was a main effect of time such that LPS significantly 
increased acetylcholine levels over time in all rats, F(15, 390) = 7.52, p < 0.001 (Figure 
3.5). There was also an interaction between prior history of PB and stress on the 
cholinergic response to LPS in the hippocampus, F(1, 26) = 6.22, p =0.019. In vehicle-
treated rats, a prior stress history attenuated the cholinergic response to LPS relative to 
NSC rats, p = 0.031. Additionally, in NSC rats, PB attenuated the acetylcholine response 
relative to vehicle-treated rats at collections 11-14, (p = 0.037, 0.016, 0.049, and 0.025, 
respectively). This attenuation of the cholinergic response to LPS during collections 11-
14 in PB-NSC rats parallels the cholinergic response of rats with a prior stress history, 
suggesting that in response to a novel systemic stressful challenge, either a prior history 
of PB or stress can significantly dampen the response cholinergic systems in the 
hippocampus. 
Acute Restraint Challenge 
In response to an acute restraint challenge, there was a significant three-way 
interaction between prior stress history, prior drug history, and time on acetylcholine 
levels in the PFC, F(11, 264)=1.83, p = 0.049 (Figure 3.6). In vehicle-treated rats, a prior 
stress history attenuated the cholinergic response to both restraint and release from 
restraint (collections 5-12) relative to NSC rats, (p = 0.010, 0.034, 0.010, 0.021, 0.024, 
0.002, 0.001, and 0.004, respectively). In contrast, PB-NSC rats exhibited a blunted 
cholinergic response to termination of the restraint stress challenge with decreased 
acetylcholine levels at collections 9 and 10 relative to vehicle-NSC rats, (p = 0.01 and 
0.013, respectively). For rats with a prior stress history, PB treatment did not   
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Figure 3.6. Cholinergic Response to a Restraint Stress Challenge in the PFC. Either a 
prior history of restraint stress or PB attenuated the cholinergic response to an acute 
restraint challenge. While a prior history of restraint stress decreased the cholinergic 
response to both restraint and the release from restraint, a prior history of PB in the 
absence of stress selectively decreased the cholinergic response to the release from 
restraint. This suggests that PB may influence cholinergic processing of the removal 
of a stressful stimulus. 
*: Significant effect of repeated restraint stress relative to vehicle-NSC rats 
$: Significant PB effect relative to vehicle-NSC rats 
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Figure 3.7. Cholinergic Response to a Restraint Stress Challenge in the 
Hippocampus. Restraint stress increased acetylcholine levels in the hippocampus in 
Vehicle-NSC rats.  Similar to results in the PFC, Vehicle-treated rats with a prior 
history of restraint stress exhibit an attenuated cholinergic response to both the 
restraint and release from restraint within the hippocampus. However, PB blocks the 
habitation of the cholinergic response in repeated restraint stress conditions. As such, 
cholinergic systems may fail to adapt to repeated psychological stress in individuals 
with a history of PB. 
*: Significant effect of repeated restraint stress relative to Vehicle-NSC rats 
#: Significant effect of PB within the repeated restraint stress condition 
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significantly alter the cholinergic response to an acute restraint challenge. These data 
suggest that in the PFC, PB treatment attenuates the cholinergic response to an acute 
novel stressor selectively in rats with no prior stress history. 
In the hippocampus, there was a significant three-way interaction between prior 
stress history, prior drug history, and time on acetylcholine levels in response to an 
acute restraint challenge, F(11, 220)=2.17, p = 0.02 (Figure 3.7). In vehicle-treated rats, a 
prior history of restraint stress attenuated the cholinergic response to a restraint 
challenge and its termination (collections 6, 8, 11), (p = 0.042, 0.029, and 0.024, 
respectively). However, rats with a prior history of PB in conjunction to repeated 
restraint stress failed to show this attenuated stress effect during restraint, instead 
exhibiting a response parallel to that of vehicle-NSC rats at collections 5 and 8, (p = 
0.011 and 0.038, respectively). These data suggest that PB impairs the habituation of 
the hippocampal cholinergic response to an acute stress challenge selectively in rats 
with a prior stress history such that they exhibit a similar cholinergic response to stress 
as that of stress-naïve rats. 
 
3.3 DISCUSSION 
This study demonstrated that a prior history of PB and stress differentially 
impact the cholinergic response to LPS and an acute restraint challenge across two brain 
regions: the prefrontal cortex and hippocampus. In the PFC, in rats with a no prior stress 
history, PB attenuates the cholinergic response to a restraint stress challenge but does 
not impact the response to an LPS challenge, suggesting that the effect of PB on 
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cholinergic function may be stressor-specific. In contrast, in rats with no prior stress 
history, PB attenuates the cholinergic response to both restraint and LPS in the 
hippocampus. Although a prior stress history attenuates the cholinergic response to 
both LPS and restraint stress in both brain regions, only the hippocampus exhibits 
synergistic effects between PB in stress. In response to a restraint challenge in the 
hippocampus, PB-stressed rats fail to exhibit an habituation of the cholinergic response 
to the restraint challenge, thus exhibiting a cholinergic response that parallels vehicle-
NSC rats as opposed to vehicle-stressed rats. The hippocampus appears to be a critical 
region where the effects of PB and stress interact to influence acetylcholine levels. 
These findings could have important implications for how recurrent life-stressors impact 
neural function in veterans with GWI.  
On a broader note, this is also the first in vivo study to demonstrate the effects 
of an LPS challenge on acetylcholine levels in the brain. Our results agree with previous 
studies which have demonstrated that acetylcholine levels in the PFC and dorsal 
hippocampus are sensitive to acute stress, increasing both in response to the stress 
challenge and again with its termination (Imperato, Puglisi-Allegra, Casolini, & Angelucci, 
1991; Mark, Rada, & Shors, 1996; Mitsushima, Masuda, & Kimura, 2003; Tajima et al., 
1996). While previous studies have demonstrated that restricted housing conditions 
attenuates the cholinergic response to an acute stress challenge in the hippocampus 
(Mitsushima, Funabashi, Shinohara, & Kimura, 2003), this is the first study to show that 
a prior history of repeated restraint stress also attenuates the cholinergic response to an 
acute stress challenge in the PFC. Therefore, this study provides valuable information on 
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how the brain responds to stressful stimuli both under normal physiological conditions 
and in a disease state. 
Cholinergic Role in Cognitive Processing of Stressful Stimuli 
 Altered cholinergic function following a history of PB pre-treatment and stress 
could have important consequences for the processing of stressful stimuli as the 
cholinergic system in the brain is associated with a variety of factors in the stress-
response. For example, this sensitivity of cholinergic systems to acute stress have been 
attributed to processing of sensory stimuli (Inglis & Fibiger, 1995; Parikh, Kozak, 
Martinez, & Sarter, 2007), desynchronization of neural networks (Chen, Sugihara, & Sur, 
2015), influencing cognitive processing during high-arousal states (Teles-Grilo Ruivo et 
al., 2017), cortical processing of anxiety-responses to stress (Hart, Sarter, & Berntson, 
1999), and top-down modulation of the cardiovascular response to stress (Hart et al., 
1999).  
Interestingly, prior history of PB attenuates the cholinergic response to an acute 
restraint challenge in the PFC and hippocampus in rats without a prior history of 
restraint. This could suggest that PB impairs processing of novel stressful stimuli, which 
could provide insight to some of the executive functioning deficits in soldiers with GWI 
who reported taking PB (Sullivan et al., 2003). In contrast, while a prior history of stress 
decreased the cholinergic response to a restraint stress and LPS challenge in the 
hippocampus, PB pretreatment disrupts this adaptation of cholinergic systems 
selectively to the restraint challenge. One possibility for this discrepancy is that PB 
disrupts the cognitive processing of stressful stimuli as well as the ability of hippocampal 
 
 
79 
 
circuits to encode those stimuli into memories. As such, cholinergic systems in the 
hippocampus exhibit divergent effects for challenges which exhibit heterotypic (novel) 
versus homotypic (parallel) stress-aspects to their prior history of stress. However, 
future studies will need to determine if this effect of PB on the neurochemical response 
in the hippocampus is selective for acetylcholine or encompasses a broader array of 
neurotransmitters (e.g. glutamate). Future studies will also need to examine if PB-
induced neurochemical deficits are stress-specific or if they are also evident during 
cognitive processing of non-stressful stimuli (e.g. novel object recognition task). 
Cholinergic Modulation of Inflammation 
 While increased cholinergic signaling is often associated with facilitation of 
cognitive function, the cholinergic system also regulates inflammatory states in the 
brain. The relationship between acetylcholine and inflammation is particularly evident 
following LPS. In our study, the cholinergic system exhibits a two-phase response to LPS 
in both the PFC and hippocampus. The first phase is rapid, peaking in the first post-LPS 
collection. While part of this increase in acetylcholine levels is likely attributable to a 
stress-response to the injection, the dose-response effect of LPS on acetylcholine at that 
time in addition to the magnitude of the response is unlikely to be attributable to the 
injection alone. One possible mechanism is that this early response is reflective of 
neurological feedback from the vagus nerve, which is a critical and rapid point of 
communication between peripheral inflammation and the brain through its afferent 
projections to the nucleus tractus solitarius (NTS) (V. Pavlov et al., 2003). LPS activates 
toll-like receptor-4 on macrophages (Hoshino et al., 1999), which then stimulates 
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nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB) and releases IL-1 
(Tracey, 2002). Vagus afferents, which have receptors for IL-1, send signals to the brain 
rapidly in response. In contrast, the latent hippocampal and PFC response to a 
peripheral injection of LPS may be more closely associated with peaking cytokine levels 
in the periphery and brain and shifting microglial phenotypes, which exhibit slower 
responses to infectious stimuli, ranging anywhere from 1-48 hours later (Erickson & 
Banks, 2011). As such, a decreased cholinergic response to LPS in PB-treated rats in the 
hippocampus at 2-3 hours post-LPS could indicate that PB shifts the brain’s cytokine 
response to LPS, which is then influencing acetylcholine levels. This could indicate, that 
the hippocampus is particularly sensitive to inflammatory changes following LPS in PB-
treated rats. However, future studies would need to confirm this by measuring cytokine 
levels directly in the brain at this time point. 
Although cytokines may be mediating the cholinergic response to LPS, 
acetylcholine also plays a critical regulatory role in mediating the cytokine response in 
the brain through interactions with microglial nicotinic α7 receptors. Nicotinic α7 
receptors are essential negative regulators of inflammation in both the peripheral and 
central systems. In the brain, α7 activation maintains the senescent state of microglia by 
inhibiting microglial expression pro-inflammatory factors (Shytle et al., 2004; H. Wang et 
al., 2003). The phenotypic states of microglia parallel that of peripheral macrophages 
and are termed M0 (senescent), M1 and M2 (Franco & Fernández-Suárez, 2015). M1 
microglia are associated with the innate immune system and respond to stimuli by 
releasing a variety of cytokines (e.g. TNF-α) that respond to an infection or neural 
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damage by stimulating phagocytosis. In contrast, M2 microglia are associated with the 
adaptive immune response through their expression of cytokines that facilitate antibody 
presentation (e.g. IL-4).  
Following exposure to LPS, microglia and macrophages both increase production 
of pro-inflammatory cytokines to facilitate phagocytosis of the endotoxin. Either an 
over-expression or under-expression of these inflammatory markers can have 
detrimental consequences in the ability of the innate immune system to respond to a 
challenge. Thus, the failure of LPS to elicit a cholinergic response in the hippocampus of 
PB-NSC rats could indicate an over-reaction of the innate immune response in the brain, 
resulting in a shift from senescent toward a pro-inflammatory and phagocytotic 
microglial phenotype. While other preclinical models of GWI have demonstrated that a 
chemical cocktail with PB induces increased density of microglial M1 phenotype (Parihar 
et al., 2013), our model provides a potential underlying mechanism for how this 
phenotypic shift in microglia could occur.  
Increased neuroinflammation has multiple detrimental consequences on 
cognitive function, including sensitivity to neuronal loss and an increased risk for 
dementia (Van Gool, Van De Beek, & Eikelenboom, 2010). This increased risk for 
cognitive deficits is largely associated with the inability of microglia to perform 
appropriate neuroprotective roles to later insults. As such, veterans who were 
administered PB during the Gulf War may have experienced impairments in the 
cholinergic negative regulatory state of microglia, sensitizing them towards later insults 
which could exacerbate neural damage and contribute to cognitive dysfunction. Indeed, 
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some animal models of GWI have demonstrated both reduced hippocampal volume, 
mild inflammatory states, and increased density of microglia relative to controls (Parihar 
et al., 2013). Addressing PB and stress induced disruptions in cholinergic function and 
the inflammatory response is increasingly critical for veterans with GWI as aging is also 
associated with a decline in cholinergic transmission and chronic low-grade 
inflammation (Norden, Muccigrosso, & Godbout, 2015; Wong, 2013). As such, 
conditions during the Gulf War may accelerate neural decline associated with aging. 
Conclusions 
 In sum, the current study demonstrated that PB changes the response of the 
central cholinergic system in the brain to various stimuli. This is critical as it 
demonstrates that regardless of whether PB did or did not cross the blood-brain barrier, 
PB compromises the function of central cholinergic systems in a brain-region specific 
manner. In the current study, a prior history of stress failed to exhibit the secondary 
increase in the cholinergic response to LPS in the hippocampus. In addition, rats with a 
prior history of PB but not stress also fail to exhibit this latent cholinergic response to 
LPS, mimicking the effects evidenced in rats with a prior repeated stress history. As 
these PB-effects were specific for the hippocampus, this suggests that the hippocampal 
cholinergic system may be particularly sensitive to PB-induced changes. Moreover, 
these PB-induced changes may be reflective of impairments in the appropriate neural 
response to cytokine-induced inflammatory signals in the brain as opposed to the vagal 
response. Deficits in the ability of the cholinergic system to adequately respond to 
stressful stimuli may directly impact cognitive function, contributing to cognitive deficits 
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evidenced in veterans with GWI. In addition, the inability of the cholinergic system to 
adequately inhibit activation of microglia could make the brain vulnerable to secondary 
insults, contributing to the progressive nature of GWI in veterans. As cholinergic systems 
also become compromised with age, it is possible that veterans with GWI could exhibit 
accelerated cognitive decline with age and age-related diseases such as Alzheimer’s.  
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CHAPTER 4 
EXPERIMENT THREE: GLUTAMATE IN GULF WAR ILLNESS
 Although cholinergic systems in both the central and peripheral nervous system 
are clearly impacted by repeated exposure to PB, glutamatergic systems may be more 
sensitive to the interactive effects between PB and stress in GWI. Repeated stress alters 
the immune profile of the adult rodent brain as well as glutamatergic tone and glial cell 
functionality, creating compounding effects and sensitizing the system to later damage 
(Banasr et al., 2010; Hinwood, Morandini, Day, & Walker, 2012; Macht & Reagan, 2017; 
Mayhew, Beart, & Walker, 2015; Tynan et al., 2013). This is likely partially due to the 
unique juxtaposition of glutamatergic synapses with glia. Two primary glial cells which 
are closely associated with glutamatergic transmission and actively respond to immune 
challenges (e.g. stress, bacterial exposure, etc.) by producing and reacting to various 
immune signals (e.g. cytokines and chemokines) are astrocytes and microglia (Lee, Liu, 
Dickson, Brosnan, & Berman, 1993; Sugama, Takenouchi, Sekiyama, Kitani, & 
Hashimoto, 2011). The following sections will discuss the relationship between 
astrocytes, microglia, glutamate, and their intersection between immune function and 
stress as this may also be an intersection between PB, stress, and cognitive dysfunction 
in veterans with GWI. 
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The quad-partite synapse: Astrocytes, Microglia, and Glutamate 
PB and stress may interact at glutamatergic synapses, interfering with plasticity 
of glutamatergic systems and driving several of the neurocognitive deficits evidenced in 
veterans with GWI. The potential for glutamatergic systems to be sensitive to stress and 
PB interactions is largely associated with the unique juxtaposition of glutamatergic 
synapses with surrounding glia. Glutamatergic synapses are quad-partite, consisting of 
glutamatergic pre- and post-synaptic terminals, astrocytes, and microglia (Schafer, 
Lehrman, & Stevens, 2013). Astrocytes modulate glutamate homeostasis, conditionally 
release vesicular glutamate, modulate blood-brain barrier permeability, coordinate 
neuronal activity via intracellular calcium waves, and regulate local cytokine release 
(Abbott, Rönnbäck, & Hansson, 2006; Bezzi et al., 2004; Chung & Benveniste, 1990; 
Cornell-Bell, Finkbeiner, Cooper, & Smith, 1990; Sugama et al., 2011). In contrast, 
microglia are a type of macrophage with highly ramified processes that rapidly extend 
and retract to survey the surrounding environment (Nimmerjahn, Kirchhoff, & 
Helmchen, 2005). They can shift between M0, M1 and M2 phenotypes which are 
associated with a variety of functions including facilitation of long-term potentiation, 
cell surveillance, neurotransmitter release, phagocytosis, tissue repair, and production 
of both pro- and anti-inflammatory cytokines (Cherry, Olschowka, & O’Banion, 2014; 
Franco & Fernández-Suárez, 2015; Hanisch & Kettenmann, 2007; Kettenmann, Kirchhoff, 
& Verkhratsky, 2013). As such, glutamate may be a key intersection between 
neurotransmission, cognitive function, and the immune systems through its dynamic 
relationship with surrounding glia.  
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Perturbations in immune function by PB could have downstream consequences 
on glia and glutamatergic transmission. As glutamatergic systems and glia in the PFC and 
hippocampus are also sensitive to repeated stress, the glutamatergic quad-partite 
synapse may be a critical point where stress and PB collide, resulting in synergistic and 
detrimental consequences on neural transmission and cognitive function. 
Interactions between Stress and Glutamate 
Perhaps some of the most well-documented effects of stress on glutamatergic 
neurons are the effects of stress on dendritic morphology (S. Cook & Wellman, 2004; 
Gould, Woolley, Frankfurt, & Mcewen, 1990; Liston et al., 2006; R.J. Liu & Aghajanian, 
2008; Jason J. Radley et al., 2008; Jason J Radley et al., 2006; Vyas, Mitra, Rao, & 
Chattarji, 2002; Watanabe et al., 1992; Woolley, Gould, & Mcewen, 1990) In males, 
chronic stress generally produces reductions in morphological complexity and density of 
mushroom spines across a variety of nonsocial (e.g. unpredictable or restraint stress) 
and social (e.g. resident-intruder and social isolation) stressors, suggesting that 
decreased glutamatergic tone is a common underlying consequence for the PFC and 
hippocampus in response to chronic stress paradigms during adulthood.  
Repeated stress also produces functional deficits in glutamate. For example, five 
days of social defeat stress produces reductions in synaptic excitability in the PFC (Urban 
& Valentino, 2017), and fourteen days of unpredictable stress decreases excitatory 
afferent activation as well as glutamatergic responses to an acute immobilization 
stressor (Jett, Bulin, Hatherall, McCartney, & Morilak, 2017). Chronic restraint stress 
reduces basal glutamate levels in the mPFC, while augmenting the stress response to a 
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novel tail pinch (Luczynski, Moquin, & Gratton, 2015). In contrast, there is no increase in 
the glutamatergic response to an acute immobilization stress challenge in rats with a 
prior history of chronic unpredictable stress relative to stress-naïve rats, suggesting that 
chronic stress attenuates the glutamatergic response to homotypic but not heterotypic 
stressors (Jett et al., 2017). Collectively, these studies highlight the versatility of the 
glutamatergic response to stress. As such, examining more than one type of stressor is 
helpful in determining stress-induced changes in glutamatergic transmission. Examining 
more than one type of stressor is particularly important for a model of GWI as 1) PB may 
further complicate the glutamatergic response to stress, and 2) humans regularly 
experience both psychological and physical stressors. 
Interactions between LPS and Glutamate 
Because of the well-documented disruptions in immune function in veterans 
with GWI, testing the neurological consequences of an immune challenge in a model of 
GWI may provide insight into how the brain’s response to bacteria could exacerbate 
cognitive dysfunction in veterans with GWI. LPS exerts divergent effects on various brain 
regions. For example, while the PFC and hippocampus are sensitive to the effects of 
restraint stress, they are particularly resistant to LPS-induced inflammatory effects 
during adulthood. Up to 10 µg/mL LPS failed to elicit either a cytokine response or shifts 
towards “activated” microglial phenotypes in neuro-glial cultures from the PFC or 
hippocampus (W.-G. Kim et al., 2000).  
However, stress can prime the immune system to a second inflammatory insult 
(Dantzer & Kelley, 1989; Dhabhar, 2014; Simmons & Broderick, 2005). Although a single 
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stress session is sufficient to induce this cross-sensitization in plasma cytokine response 
to an LPS challenge (J. D. Johnson et al., 2002), these effects on the brain are particularly 
variable depending on the region being examined. For example, a single exposure to 
inescapable tail shock sensitizes the hypothalamic, pituitary and cerebellar but not the 
cortical or hippocampal cytokine response to LPS challenge (J. D. Johnson et al., 2002), 
suggesting that the adult PFC and hippocampus are resistant to immune sensitization 
following an acute challenge of either LPS or stress. In addition, some evidence suggests 
that the PFC and hippocampus have different susceptibilities to oxidative stress 
following chronic isolation stress with the PFC being the more sensitive of the two 
(Zlatković et al., 2014). Due to the particular variations in resistance of the PFC and 
hippocampus to an LPS challenge, PB-induced disruptions in the quad-partite synapse 
may selectively sensitize these regions to an LPS challenge with the hippocampus being 
the more sensitive of the two regions. As such, veterans who took PB during 
deployment could be more sensitive to hippocampal glutamatergic changes following a 
bacterial infection with consequential disruption of proper functioning in learning and 
memory circuits. 
Current Experiment and Hypotheses 
 To address whether PB and repeated restraint stress interact to prime the 
glutamatergic response to inflammatory stimuli, the current study used a rodent model 
of GWI in combination with in vivo microdialysis to examine the neurochemical 
response to an immune challenge and an acute stress challenge. The glutamatergic 
response was assessed in two brain regions: the PFC and the hippocampus. These brain 
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regions were targeted due to 1) the critical roles of glutamate in their facilitation of 
cognitive function, and 2) their different susceptibilities to stress-induced inflammation. 
We tested the hypothesis that combinations of PB and stress increased the 
glutamatergic response to an innate immune challenge, thus potentially contributing 
cognitive deficits evidenced in veterans with GWI. Specifically, while neither the PFC nor 
hippocampus were hypothesized to react to LPS in vehicle-NSC rats, both regions were 
hypothesized to exhibit increases in the glutamatergic response following repeated 
restraint stress. PB was hypothesized to exacerbate this effect, and the PFC was 
hypothesized to be the most sensitive to the combined effects of PB and stress.  
In addition, we tested whether an acute psychological stressor (restraint stress) 
produced similar deficits in the glutamatergic response in rats with a prior history of PB 
and repeated stress. Although PB is not hypothesized to impact basal levels of 
glutamatergic function, PB is hypothesized to interact with stress to produce 
impairments in the habituation of the glutamatergic response to the restraint stress 
challenge in both the PFC and hippocampus.  
 
4.1 METHODS AND MATERIALS 
Microdialysis samples were the same collections from the same rats used for 
acetylcholine analysis, and as such, all procedures including animal handling, the GWI 
paradigm, surgery, sample collection, and euthanasia were identical to Experiment Two. 
In each sample, acetylcholine was analyzed first, and glutamate was analyzed second. As 
such, samples went through one additional freeze-thaw cycle prior to glutamate 
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analysis. This order of analysis was performed as acetylcholine is more sensitive to 
freeze-thaw cycles than glutamate. Results from the plasma collected during the first 
and second microdialysis sessions will be discussed in this section.  
Cytokine Analysis 
Plasma cytokines in response to LPS were analyzed using a 12-Plex Th1/Th2 Bio-
Plex kit. Tail bleeds were performed immediately at the termination of the first 
microdialysis session, approximately 3 hours after LPS administration. Blood was 
collected on ice and then immediately spun down in a microcentrifuge at 4oC for 15 
minutes × 30,000 g. The plasma supernatant was aspirated and stored in centrifuge 
tubes at -80oC for later analysis.  
The Bio-Plex assay uses premixed coupled magnetic beads and detection 
antibodies to detect 12 different rat cytokines. Solutions for the assay were brought to 
room temperature 30 minutes prior to initiation of assay procedures. Eight four-fold 
dilution standards were prepared using the provided diluent and reconstituted 
standard, and samples were thawed and diluted 1:4 with diluent. 288 µL of 20x beads 
were vortexed for 30 seconds and then diluted with 5472 µL of assay buffer for a total 
volume of 5760 µL. 50 µL of the diluted beads were then added to be bottom of a 96-
well plate, followed by 50 µL of standards and samples. The assay plate incubated on an 
orbital shaker plate for 1 hour at room temperature. After 3 washes with wash buffer, 
25 µL of detection antibody was added to each well, followed by a 30 minute incubation 
at room temperature on an orbital shaker. The detection antibody was washed from the 
plate with 3 washes using wash buffer. 50 µL of SA-PE will be added to each well and the 
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plate was incubated on an orbital shaker at room temperature for 10 minutes. After the 
incubation, the plate was washed 3 times with wash buffer and then the beads were re-
suspended in 125 µL assay buffer. After 30 seconds, the plate was read on a plate reader 
using high photomultiplier voltage. Results were interpreted from a logarithmic 
standard curve. Due to assay to assay variability, data at each time point were expressed 
as a percentage of the mean of their respective vehicle-NSC groups in order to allow 
clear interpretations of the data. 
High Performance Liquid Chromatography for Glutamate 
 In random order from sample collection, 7.5 µL of previously frozen 
microdialysate sample was loaded onto an EiCom GU-GEL polymer resin based analytical 
column where glutamate was isolated from other biogenic compounds in interaction 
with a mobile phase consisting of 50 mM ammonium chloride-ammonia, 250 mg/L 
hexadecyltrimethylammonium bromide, and 10 µL/L of 5 mg/mL 2Na EDTA, pH 7.2. 
Afterwards, a glutamate oxidase enzyme column metabolized glutamate into hydrogen 
peroxide and 2-ketoglutalate. The hydrogen peroxide was oxidized at the platinum 
electrochemical detector with an applied current of +500 mV, resulting in O2, 2H+, and 
2e. The potential was read using the Epsilon computer controlled detector system from 
BASi. Concentration of glutamate in samples was interpolated against a three-point 
standard curve of 3, 1, and 0.1 µM glutamate. 
Statistical Analyses 
Results were calculated as a 2×2×16 mixed ANOVA for the LPS session and a 
2×2×12 mixed ANOVA for the restraint challenge session. For between subjects, this 
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experiment had 2 levels of drug treatment (vehicle, PB), 2 levels of stress (NSC, 
stressed). Within-subjects repeated measures consisted of 16 levels, representing the 16 
consecutive collections during microdialysis for the LPS challenge. The restraint stress 
challenge had a total of 12 collections: 4 baseline, 4 during restraint, 4 post-restraint. 
Following significant interactions, simple main effects post hoc tests were performed 
with Bonferroni post-hoc corrections for family-wise error.  
Power analyses for in vivo microdialysis were performed a priori with an effect 
size of 0.8 and α=0.05; analyses suggested that a sample size of n=8 per group with a 
total N = 32 would be sufficient for achieving statistical significance. After correcting for 
statistical outliers and other complications during microdialysis and HPLC (e.g. erratic 
baseline, undetectable analytes, loss of cannula, broken probe), actual sample size for 
each condition was as follows: 
Table 4.1 Sample Size for Each Condition in GWI Paradigm 
 PFC Hippocampus 
 LPS Restraint LPS Restraint 
Vehicle-NSC 8 6 8 7 
PB-NSC 9 6 8 5 
Vehicle-Stressed 6 5 5 4 
PB-Stressed 7 6 7 6 
 
4.2 RESULTS 
GWI In Vivo Microdialysis: Glutamate  
Basal Levels of Glutamate 
 On the first day of microdialysis, prior to the LPS challenge, neither prior history 
of PB nor restraint stress significantly impacted basal glutamate levels in the PFC, F(1,   
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Figure 4.1 Basal Levels of Glutamate on the First Day of Microdialysis. On the 
first day of microdialysis, prior to the LPS challenge, there was no effect of 
either PB or stress on basal glutamate levels in the PFC or hippocampus. This 
suggests that neither a history of PB nor restraint stress either independently 
or in interaction impact affect basal glutamate levels in either brain region. 
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22) = 0.62, p = 0.44 , or hippocampus, F(1, 24) = 0.18, p = 0.67 (Figure 4.1). On the 
second day of microdialysis, prior to the restraint challenge, the hippocampus still did 
not exhibit any differences in basal acetylcholine levels between any groups, F(1, 18) = 
0.03, p = 0.87. However, on the second day of microdialysis, there was a significant 
cross-over interaction between PB and stress on basal glutamate levels in the PFC, F(1, 
21) = 12.32, p = 0.045 (Table 4.2). In this cross-over interaction, glutamate was reduced 
in PB-NSC and vehicle-stressed rats relative to vehicle-NSC and PB-stressed 
counterparts. This shift in basal glutamate levels in the PFC on the second day of 
microdialysis is difficult to interpret as it could be a function of several factors including 
differential recovery from probe damage, residual effects of LPS, or self-selection as the 
second day of microdialysis had a lower n-size due to experimental complications (e.g. 
probe breaking). 
 
Table 4.2 Basal Glutamate Levels on Day Two of Microdialysis  
 PFC Hippocampus 
Vehicle-NSC 1.18 ± 0.40 1.83 ± 0.88 
PB-NSC 0.58 ± 0.07* 0.55 ± 0.21 
Vehicle-Stressed 0.58 ± 0.09* 3.37 ± 0.46 
PB-Stressed 1.11 ± 0.29 2.38± 1.07 
*significant cross-over interaction, p = 0.045; Data expressed as mean ±SEM (µM) 
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Figure 4.2. Glutamate Response to an LPS Challenge in the PFC. There was a main 
effect of drug treatment on glutamate levels following LPS in the PFC. Specifically, 
although glutamatergic systems showed no response to LPS in vehicle-NSC 
conditions, there was decreased glutamatergic signaling in response to LPS 
selectively in PB-treated rats starting at the 8th collection with the exception of 
collection 10. This suggests that PB treatment primes glutamatergic systems for 
later immune challenges. Decreased glutamate levels in the PFC following LPS 
could indicate sensitivity of this brain region to LPS-induced deficits in synaptic 
plasticity.  
*: Significant effect of PB relative to vehicle-treated rats, p < 0.05 
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Figure 4.3. Glutamate Response to an LPS Challenge in the Hippocampus. Unlike in 
the PFC, vehicle-NSC rats exhibit a depression in glutamatergic levels in response to 
LPS, suggesting that this brain region may be more sensitive to the effects of LPS. PB-
stressed rats fail to show this LPS-induced depression in glutamate, suggesting that 
PB and stress interact to influence how the hippocampus responds to a systemic 
stressor. 
*: PB-stressed rats significantly different from vehicle-treated rats, p < 0.05 
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LPS Challenge 
In the PFC, there is a significant interaction between time and PB treatment on 
the glutamatergic response to an LPS challenge, F(15, 360) = 3.82, p <0.001 (Figure 4.2). 
Specifically, after intraperitoneal injection of LPS, glutamate levels significantly 
decreased in PB compared to vehicle-treated rats at collections 8-9 and 12-16, (p = 
0.022, 0.008, 0.006, 0.016, 0.010, 0.037, 0.016, respectively). These data suggest that PB 
impacts the glutamatergic response to an LPS challenge in the PFC, resulting in a 
significant reduction in glutamate levels. 
In the hippocampus, there is a significant interaction between a prior history of 
PB treatment and time on the glutamatergic response to LPS, F(15, 360)=1.77, p = 0.037 
(Figure 4.3). There is also a trend for an interaction between prior stress history and 
drug treatment on the glutamatergic response to LPS, F(1, 24)=4.00, p = 0.057. 
Specifically, while LPS reduces glutamate levels in vehicle-treated rats with a prior 
history of restraint stress, glutamate fails to decrease in response to LPS in rats PB-
stressed rats relative to their vehicle-stressed counterparts at collections 9, 13, and 16, 
(p = 0.04, 0.037, and 0.004, respectively). This suggests that PB interacts with stress to 
influence the glutamatergic response to a novel systemic stressor in the hippocampus. 
Acute Restraint challenge 
Prior stress history and prior drug history interacted over time to influence the 
glutamatergic response to an acute restraint challenge in the PFC, F(11, 209)=1.98, 
p=0.031 (Figure 4.4). Specifically, rats which experienced a prior restraint stress history 
failed to exhibit a glutamatergic response to the acute restraint challenge (collections 5   
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Figure 4.4. Glutamate Response to a Restraint Stress Challenge in the PFC. Restraint 
stress produces an acute increase in glutamatergic levels in the PFC during the 
restraint challenge, followed by a rapid return to baseline after the stressor is 
removed. There is no increase in glutamate levels in rats with a prior stress history in 
this brain region. In contrast, rats with a prior history of PB but not restraint stress 
exhibit climbing levels of glutamate even after removal of the stressor, possibly 
suggesting an inability of glutamatergic systems to recover from this experience.  
*: significant effect of stress, p < 0.05 
$: PB-NSC rats significantly different from vehicle-NSC rats, p < 0.05 
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2
5 0
1 0 0
1 5 0
2 0 0
2 5 0
C o lle c tio n  #  (1 5  m in )
%
 B
a
s
e
li
n
e
 (
G
lu
)
V e h ic le -S tre s s e d
P B -N S C
P B -S tre s s e d
V e h ic le -N S C *
R e s tra in t
$
$
$
* *
P r e fr o n ta l C o rt e x
 
 
99 
 
 
  
Figure 4.5. Glutamate Response to a Restraint Stress Challenge in the 
Hippocampus. A prior history of restraint stress increases the glutamatergic response 
to a restraint stress challenge in non-stressed vehicle-treated rats but depresses the 
glutamatergic response to a restraint stress challenge in vehicle-treated rats. 
However, PB blocks this stress-adaptation of the glutamatergic response in rats with 
a prior stress history. This suggests that PB impairs the ability of glutamatergic 
circuits to adapt to prior experience, providing a potential underlying mechanism for 
the memory impairments evidenced in veterans with GWI. 
*: Significant effect of prior stress history in vehicle-treated rats, p < 0.05 
#: Significant effect of PB in rats with a prior stress history, p < 0.05 
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and 7), unlike vehicle-NSC rats, (p = 0.008 and 0.022, respectively). In contrast, 
glutamatergic levels in response to restraint remained elevated following release from 
restraints selectively in the PB-NSC condition (collections 11 and 12), suggesting that PB 
interferes with the ability of the glutamatergic system to recover from an acute stress 
challenge in the PFC, (p = 0.015 and 0.011, respectively). 
In the hippocampus, there was a significant time × drug treatment, F(11, 198) = 
2.28, p = 0.01, and time × stress interaction, F(11, 198) = 3.87, p < 0.001. Specifically, in 
rats with a prior history of restraint stress, there is a significant effect of drug treatment 
at collection 5, 6, 7, 8, and 9, (p = 0.019, 0.005, 0.041, 0.035, and 0.037, respectively). At 
each of these time points, a prior stress history decreased the glutamatergic response to 
restraint, but a combined history with PB blocked this stress-effect. This suggests that 
PB impairs the adaptation of the glutamatergic response in the hippocampus to 
psychological stress (Figure 4.5). 
Cytokine Response to LPS 
A prior history of PB selectively attenuated the LPS-induced increase in IL-6, F(1, 
24) = 7.30, p = 0.01 (Figure 4.6). No other cytokines were significantly impacted by 
either stress or drug treatment, although there was a trend for TNF-α levels to be 
attenuated in PB-treated rats, F(1, 24) = 4.19, p = 0.05 (Table 4.3). This suggests that 1) 
IL-6 may be particularly sensitive to the effects of PB, and 2) a prior history of PB impairs 
innate immune system’s ability to mount an appropriate response to an LPS challenge.  
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Table 4.3 Cytokine Levels Three Hours after LPS as a Percent of Vehicle—NSC 
Cytokine Vehicle-NSC Vehicle-Stressed PB-NSC PB-Stressed 
IL-1α 100.0 ± 4.1 76.7 ± 13.9 98.3 ± 7.4 95.22 ± 9.4 
IL-1β 100.0 ± 6.4 94.1 ± 19.3 78.8 ± 8.0 77.9 ± 11.6 
IL-2 100.0 ± 4.2 75.9 ± 19.7 91.0 ± 7.8 94.3 ± 8.0 
IL-4 100.0 ± 3.7 72.5 ± 20.5 88.1 ± 8.6 90.0 ± 7.7 
IL-5 100.0 ± 2.1 79.8 ± 14.6 94.3 ± 5.6 95.5 ± 4.9 
IL-6 100.0 ± 14.2 105.1 ± 32.2 56.0 ± 7.2* 65.2 ± 9.3* 
IL-10 100.0 ± 4.0 76.8 ± 16.2 85.9 ± 7.3 87.9 ± 6.5 
IL-12 100.0 ± 5.6 73.0 ± 21.7 86.4 ± 10.2 88.5 ± 11.1 
IL-13 100.0 ± 6.8 76.4 ± 21.8 92.6 ± 11.2 98.9 ± 11.6 
TNF-α 100.0 ± 10.9 108.9 ± 23.2 66.2 ± 7.7# 88.1 ± 14.9# 
IFN-γ 100.0 ± 3.4 79.1 ± 15.4 83.4 ± 7.0 92.0 ± 8.2 
GM-CSF 100.0 ± 6.4 71.8 ± 22.7 86.9 ± 10.3 93.3 ± 11.0 
* values are significantly different from Vehicle-NSC; #: trend for a significant effect relative to 
Vehicle-NSC rats 
 
4.3 DISCUSSION 
 The current study used a rodent model of GWI to demonstrate that 1) the 
response of glutamatergic systems to systemic or psychological stress is disrupted 
synergistically by combinations of PB and repeated restraint stress, and 2) the effect of 
PB on glutamatergic systems is dependent upon the brain region, the type of challenge, 
and the stress history. In rats with no history of restraint stress, PB preferentially 
increases the glutamatergic response relative to vehicle-NSC rats following a restraint 
stress challenge in the PFC but not the hippocampus. In contrast, when LPS was 
administered as a systemic stress challenge, there was a decrease in the glutamatergic 
response to LPS in PB-treated rats regardless of their stress history. This suggests that 
PB disrupts how the glutamatergic system in the PFC processes novel stressful stimuli. 
Because cortical activity has important consequences for how the hippocampus encodes 
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Figure 4.6. Plasma IL-6 Response to an LPS Challenge: 3 hours Post-Injection. LPS 
increased cytokine levels in all rats relative to a sample of Day 14 tail bleeds from 
vehicle-NSC rats in the absence of LPS. However, the LPS-induced increase in IL-6 was 
significantly attenuated by a prior history of PB. This suggests that PB impairs the 
ability of the innate immune system to mount an appropriate response to a systemic 
stressor.  
*: Significant effect of PB relative to vehicle-treated rats, p < 0.05 
#: Significant effect of LPS, p < 0.05 
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a stressful event, shifts in cortical processing of stressful stimuli could have profound 
consequences on the hippocampal response following repeated exposures to stress.  
When the stressor is unique to prior stressful experiences (e.g. LPS challenge is 
heterotypic to restraint stress), then the hippocampal glutamatergic response to that 
challenge is similar in vehicle-NSC rats to both vehicle-stressed and PB-NSC rats. 
However, in rats with both a history of PB and repeated restraint stress, LPS fails to 
induce a change in glutamatergic levels. This suggests that PB and repeated restraint 
stress interact to selectively attenuate how the hippocampus responds to a systemic 
stressor. This selective effect of PB and repeated restraint stress on glutamatergic 
systems is also evident following a restraint stress challenge. In this case, rats with a 
prior history of PB and restraint stress exhibit a parallel glutamatergic response to the 
restraint stress challenge as restraint stress naïve rats. That is, glutamatergic levels in 
the hippocampus are similar in PB-stressed rats as vehicle or PB-NSC rats following a 
restraint challenge. The failure of glutamatergic systems to adapt in the hippocampus to 
repeated exposures of a stressful stimulus could be attributable to a combination of 
factors. One possible mechanism is that PB-driven shifts in the cortical processing of 
stressful stimuli could impair the ability of the hippocampus to form an appropriate 
memory circuit to encode the stressful stimulus. Another possibility is that PB-driven 
changes in the cytokine response to stress may impair the ability of the glutamatergic 
systems to facilitate long-term potentiation in the hippocampus. The subsequent 
sections will address each of these possibilities. 
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Cortical Processing of Stressful Stimuli 
 In the PFC, a prior history of PB accentuates the glutamatergic response to 
restraint stress but attenuates the glutamatergic response to LPS in rats with no prior 
stress history. An important distinction between the glutamatergic response for each of 
these stressors is that the PFC is typically resistant to the effects of LPS but sensitive to 
the effects of restraint stress (Pablos et al., 2006; Moghaddam, 1993). As such, a 
decrease in the glutamatergic response following LPS administration in PB-treated rats 
could indicate that PB increases the sensitivity of the PFC to inflammatory effects. In 
addition, glutamatergic levels in the PFC fail to recover following the termination of 
restraint stress in rats with no prior restraint history. This suggests that PB alters the 
cortical processing of novel stressful stimuli such that when veterans returning from the 
Gulf War are subjected to new stressors, glutamatergic systems may not respond in an 
adaptive manner. For example, climbing glutamate levels following the termination of 
restraint stress in PB-treated rats could create a predisposition to neurotoxicity 
following psychological stress. In contrast, depression of glutamatergic levels in 
response to LPS may indicate sensitivity to sickness behaviors, including impairments in 
complex cognitive tasks (Moghaddam, Adams, Verma, & Daly, 1997; Verma et al., 1996; 
Walker et al., 2013). Further studies would need to be conducted to discern whether 
LPS exacerbates cognitive deficits following PB and whether PFC systems are sensitized 
to excitotoxicity following a restraint challenge.  
Cytokines and Glutamate 
Following an LPS challenge, rats with a prior history of PB treatment exhibit an 
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attenuated response of IL-6 to this challenge. Although we measured Il-6 levels in the 
periphery, studies have demonstrated that brain levels of IL-6 follow a similar pattern to 
plasma levels at this time point after LPS administration (Erickson & Banks, 2011). IL-6 is 
intimately linked with memory formation in the hippocampus, although its role in the 
facilitation or suppression of memory formation is extremely complex. For example, 
early studies using ex vivo hippocampal slice electrophysiology demonstrated that high 
levels of IL-6 impair LTP (A.-J. Li, Katafuchi, Oda, Hori, & Oomura, 1997). Other studies 
used knockout models for IL-6 to demonstrate that IL-6 -/- mice are protected against 
LPS-induced deficits in Morris water maze performance (Sparkman et al., 2006). This 
idea that IL-6 impairs learning and memory predominated the literature for several 
years.  
However, a more complex role of IL-6 in health and disease began to emerge in 
the late 1990s (Gadient & Otten, 1997) . This evolution of pleiotropic roles of cytokines 
parallels the expansion of our understanding for the complex relationships between 
cytokines and neurotransmitter systems. IL-6, among other cytokines, remains an 
important point of communication between neurons and glia in normal development 
(Prieto & Cotman, 2017). For example, mouse IL-6 knockout models show profound 
deficits in recognition memory and spatial memory relative to wild-type mice (Baier, 
May, Scheller, Rose-John, & Schiffelholz, 2009; Hryniewicz, Bialuk, Kamiński, & 
Winnicka, 2007). In addition, other ex vivo and in vivo studies have demonstrated that 
LTP induces IL-6 expression (Balschun et al., 2004), and that the induction of IL-6 is 
critical for modulating the temporal specificity of LTP within local circuits. As the 
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induction of IL-6 following a tetanus is mediated by NMDA receptors, this suggests that 
changes in glutamatergic signaling in response to a stressful stimulus could directly 
impact the local cytokine response, which consequently would impact the specificity of 
the plasticity of local circuits. Other studies have found a similar relationship between 
glutamate and IL-6, with one study suggesting that genetic overexpression of IL-6 
produces an excitatory-inhibitory shift by stimulating the formation of excitatory 
synapses and interfering with the formation of inhibitory synapses in the hippocampus 
(Wei et al., 2012).  
This expanding view of the role of IL-6 in memory suggests that under normal 
conditions, IL-6 is an important mediator of memory formation through its interaction 
with excitatory and inhibitory circuits, and deviations in the relationship between 
glutamate and IL-6 may impair the formation of appropriate memory-dependent 
plasticity in circuits. Following an LPS challenge, rats with a history of both stress and PB 
exhibit no change in glutamate levels in the hippocampus in addition to deficits in levels 
of peripheral IL-6. If these peripheral levels of IL-6 parallel that in the hippocampus, it is 
possible that the cellular dynamics between IL-6 and glutamate in facilitating the 
appropriate formation of memory-circuits has been disrupted, resulting in deficits in 
plasticity in this system.  
However, cytokines often work in concert to achieve different effects. As such, it 
is important to note that we also saw a trend for decreased TNF-α (p  = 0.05) in PB-
treated rats following LPS administration. Like IL-6, TNF-α is also intimately linked with 
glutamate and LTP. However, whereas IL-6 primarily interacts with NMDA receptors, 
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TNF-α upregulates AMPA receptors to influence synaptic scaling (Beattle et al., 2002). 
Thus, TNF-α is also an important mediator of cellular mechanisms underlying memory 
formation. Combined deficits in levels of IL-6 and TNF-α would produce compounding 
effects on the efficacy of glutamatergic systems to facilitate event-driven plasticity in 
the central nervous system. As such, this shift in the signaling between cytokines and 
excitatory neurotransmission may underlie some of the memory-deficits evidenced in 
veterans with GWI. Future studies will need to verify 1) if these peripheral changes in IL-
6 match brain levels in this model and 2) if manipulation of either IL-6, TNF-α, or 
glutamate through agonists and antagonists can shift memory performance in a model 
of GWI. 
Conclusions 
 In sum, a history of PB and repeated restraint stress interact to preferentially 
impact the glutamatergic response in the hippocampus to either a systemic or 
psychological stress challenge. In contrast, PB preferentially impacts how the PFC 
processes novel stressful stimuli. These results suggest that alterations in the ability of 
excitatory neurotransmitter systems to respond appropriately to stressful events may 
underlie memory consolidation problems in veterans with GWI.  
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CHAPTER 5 
MODELING THE PATHOGENESIS OF GULF WAR ILLNESS
 Collectively, these studies provide insight as to how PB and stress may have 
independently and in combination adversely impacted peripheral and central 
physiology, thus providing a potential mechanism by which PB and stress may have 
caused impairments in veterans from the Gulf War. This discussion will therefore first 
summarize the independent effects that PB and stress each exhibited on physiology and 
behavior. Secondly, the synergistic effects between PB and stress will be discussed in 
the context of modeling the pathogenesis of GWI. 
 
5.1 EFFECTS OF PB ALONE 
 There has been a long-standing debate about the effects of PB on physiology. As 
an effective treatment for the muscular disorder myasthenia gravis with decades of 
history, long-term detrimental effects of PB when given to soldiers was not anticipated 
(J. E. Cook, Kolka, & Wenger, 1992). In addition, PB was not thought to cross the blood 
brain barrier and therefore not anticipated to have any cognitive effects. However, our 
study demonstrates that PB, even in the absence of stress, changes both peripheral 
physiology and central neurochemistry (Figure 5.1).  
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Figure 5.1. Impact of PB in NSC Rats. On the last day of treatment (day 14), PB 
decreases AChE activity but produces robust increases in both Th1 and Th2 cytokines. 
Although PB in the absence of stress does not impact freezing behavior in a 
conditioned freezing paradigm at any time point, PB does produce several central 
neurological changes one-week post treatment. Generally, cholinergic systems 
exhibit an attenuated response to challenges in both brain regions. The effect of PB 
on glutamate levels is mixed with selective effects on the glutamatergic response in 
the PFC. As such, PB may prime cortical systems to shift processing of novel stressful 
events, which could have consequences for how veterans processed stressful stimuli 
upon returning from deployment. 
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PB Disrupts the Innate Immune System  
 One of the most surprising peripheral effects evidenced in PB-treated rats was 
the effect on the immune system. Cholinesterase inhibitors, like PB, have typically been 
considered anti-inflammatory through their ability to augment acetylcholine levels in 
the parasympathetic nervous system and increasing activity at nicotinic α7 cholinergic 
receptors on tissue macrophages as part of the vagus anti-inflammatory pathway (V. A. 
Pavlov et al., 2009; Tracey, 2002). However, this anti-inflammatory effect of 
cholinesterase inhibitors is typically examined in the context of another pro-
inflammatory stimulus such as LPS or a disease state such as delirium, 
encephalomyelitis, or Alzheimer’s (Nizri et al., 2008; V. A. Pavlov et al., 2009; Reale et 
al., 2004; Van Gool et al., 2010). While we saw an anti-inflammatory effect of PB in the 
context of stress, our study also demonstrated that in the absence of another 
inflammatory stimulus, repeated administration of PB disrupts the innate immune 
response, increasing levels of both pro- and anti-inflammatory cytokines. At basal levels, 
this effect of PB on inflammation appears transitory as it disappears within a week of 
the cessation of treatment. However, an LPS challenge at one-week post treatment 
demonstrates that PB continues to disrupt the ability of the innate immune system to 
adaptively respond to an immune challenge: PB-treated rats exhibit an attenuated 
response of IL-6 and TNF-α relative to controls. These results suggest that it is likely that 
the effects of PB on the innate immune system provides the first catalyst to tip the 
homeostatic balance of physiological systems, thereby priming the organism to the 
effects of a later stressor. 
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PB Disrupts the Central Cholinergic System 
 A major point of contention with the administration of PB in soldiers is whether 
it crossed the blood brain barrier. While some evidence suggests that stress creates a 
leaky blood brain barrier, allowing PB to cross directly into the central nervous system 
(Abdel-Rahman et al., 2002), other studies have failed to replicate these findings 
(Amourette et al., 2009; Grauer et al., 2000; Kant et al., 2001; Song et al., 2002; Tian et 
al., 2002). Our study suggests that regardless of whether PB does or does not cross the 
blood-brain barrier, it produces profound effects on central cholinergic function. 
Importantly, the effects of PB on the central nervous system are not evident in the 
absence of a stimulus which would challenge the cholinergic system. This could explain 
some of the inconsistent results with previous literature on how PB impacts brain 
acetylcholine levels.  
Generally, following either an immune or stress challenge, a prior history of PB 
attenuates the cholinergic response. As a history of restraint stress also attenuates the 
cholinergic response to a challenge, these data suggest that PB mimics the effect of 
stress on cholinergic systems but does not exacerbate the effects of stress in rats with a 
history of both PB and restraint stress. These effects of PB on central cholinergic 
function have multiple consequences for cognition and could provide insight as to how 
central cholinergic systems respond differently in veterans with GWI, thus providing a 
mechanism explaining their cognitive deficits. In particular, these results suggest that PB 
may impair cortical cholinergic processing of novel stressful stimuli.  
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Post-deployment in veterans is associated with a variety of novel stressors 
including underemployment, financial decline, marital stress, substance abuse, and 
stress associated with post-deployment care and hospitalization from war-related 
injuries (Spelman, Hunt, Seal, & Burgo-Black, 2012). Veterans administered PB during 
deployment may processes these stressors differently. Not only would an attenuated 
cholinergic response to these types of stressors impair cognitive functioning, but it 
would also decrease the ability of central cholinergic systems to properly regulate 
microglial inflammatory phenotypes. As such, veterans who were administered PB 
during the war may also be more sensitive to the inflammatory consequences of post-
war stressors. As rates of GWI continue to climb and symptoms in veterans become 
more exacerbated over time (B. Li, Mahan, Kang, Eisen, & Engel, 2011), shifts in how the 
cholinergic system responds to new stressful events may be the catalyst for the 
progressive state of this illness.  
 
5.2 EFFECTS OF STRESS ALONE 
Repeated restraint stress produces several changes in the periphery, the brain, 
and behavior (Figure 5.2). One week after the end of restraint stress, rats with prior 
stress histories exhibit impairments in contextual fear conditioning, suggesting a 
memory deficit. This deficit in conditioned freezing is paralleled by shifts in both 
cholinergic and glutamatergic responses to stressful challenges in the PFC and 
hippocampus. Our results parallel a plethora of literature which suggests that   
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Figure 5.2. Impact of Restraint Stress in Vehicle-treated Rats. Stress increases 
corticosterone levels following repeated restraint stress in vehicle-treated rats and 
increases IL-1α and IL-5 on the last day of treatment. Conditioned freezing is also 
attenuated one week following the end of treatment but increased three months post-
treatment. Cholinergic and glutamatergic systems also demonstrated robust stress-
induced adaptations to LPS and restraint stress challenges with parallel responses 
between the PFC and hippocampus. A prior history of restraint stress reduces the 
cholinergic response to stress ubiquitously. However, glutamate decreases in response 
to restraint stress but responds like vehicle-NSC rats to a novel stressor (LPS). 
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neurological systems adapt to repeated stress. Interestingly, glutamatergic and 
cholinergic systems exhibit divergent responses depending on the type of stress 
challenge (i.e. LPS versus restraint stress). A prior history of restraint stress reduces the 
cholinergic response to a novel (LPS) or restraint stress challenge. The glutamatergic 
response to a restraint stress challenge is also decreased in vehicle-stressed rats relative 
to vehicle-NSC rats. However, glutamatergic systems do not exhibit this attenuated 
response to a novel challenge, such as LPS. This divergent response of glutamate 
following repeated restraint stress closely parallels the glucocorticoid response to 
homotypic and heterotypic stressors (Kopp, Wick, & Herman, 2013; Lui et al., 2012). As 
pyramidal neurons are extremely sensitive to the effects of repeated stress, exhibiting 
highly reproducible glucocorticoid-induced shifts in morphology (B. McEwen & 
Morrison, 2013), it is possible that glucocorticoids in part mediate these divergent 
patterns in the glutamatergic response to an LPS and restraint stress challenge in 
vehicle-treated rats with a prior history of repeated restraint.   
 
5.3 SYNERGISTIC EFFECTS OF PB AND STRESS 
 Independently, PB and stress produce several changes in both peripheral 
markers, the central nervous system, and behavior (Figure 5.3). PB and stress exhibit 
synergistic effects on conditioned freezing one week following the cessation of 
treatment, suggesting that PB exacerbates memory deficits of repeated stress. These 
memory deficits are paralleled by shifts in neurochemical processing of an LPS or 
restraint stress challenge. However, while the shifts in the neurochemical response to   
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Figure 5.3. Interaction between Restraint Stress and PB. Acutely, PB decrease AChE 
while stress increases corticosterone. PB in the context of stress exhibits anti-
inflammatory effects on cytokines. Conditioned freezing is also transiently decreased 
one week following the end of treatment. Hippocampal systems are particularly 
sensitive to the synergistic effects of PB and stress at this time. For example, 
glutamatergic levels in the hippocampus fail to respond to an LPS challenge, unlike 
both vehicle-NSC and vehicle-stressed rats which exhibit a decrease in glutamate in 
response to LPS in the hippocampus. In addition, while glutamatergic and cholinergic 
systems in vehicle-stressed rats exhibit an attenuated response to restraint stress, 
PB-stressed rats respond in parallel to vehicle-NSC rats. 
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these challenges in the PFC are associated with the effects of PB or stress 
independently, PB and stress synergistically impact hippocampal neurochemistry so that 
the combined effects of PB and stress on hippocampal function diverge from vehicle-
stressed counterparts. For example, following a restraint stress challenge, both 
cholinergic and glutamatergic systems in PB-stressed rats respond like the systems in 
vehicle-NSC rats instead of vehicle-treated stress counterparts. In addition, 
glutamatergic but not cholinergic systems in the hippocampus are uniquely impacted 
following a restraint stress challenge, where unlike all other groups, glutamatergic 
systems in PB-stressed rats fail to respond to an LPS challenge in the hippocampus. 
These results suggest that glutamatergic systems in the hippocampus are the most 
robustly affected by the combined effects of PB and repeated restraint stress. Because 
glutamatergic systems are also sensitive to inflammation due to the close juxtaposition 
of their synapses with microglia and astrocytes, dysregulation of glutamate may be 
compounded by the robust effects of PB and stress on immune function, exacerbating 
deficits in neural plasticity and increasing sensitivity to damage from oxidative stress. 
This could suggest that targeting either cytokines or glutamate may be an optimal 
treatment strategy for reversing cognitive deficits in veterans with GWI or slowing the 
progression of the illness. 
Modeling Peripheral Interactions between PB and Stress 
The most likely point for PB and stress to have interacted peripherally to produce 
these changes in brain neurochemistry and behavior is the immune system (Figure 5.4).   
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Figure 5.4. Peripheral Interactions between Restraint Stress and PB. PB increases 
peripheral acetylcholine levels through inhibition of AChE. Increased acetylcholine 
would increase activity at nicotinic receptors on macrophages, which would inhibit 
cytokine release, and chromaffin granules in the adrenal medulla, which would 
release epinephrine and norepinephrine to stimulate adrenergic receptors on 
macrophages and increase cytokine release. Stress also activates the sympathetic 
nervous system to release epinephrine and norephinephrine from the adrenal 
medulla as well as activate the HPA axis to increase glucocorticoid release from the 
adrenal cortex. Glucocorticoids inhibit the inflammatory response through activity on 
glucocorticoid receptors within the macrophage cytoplasm. These conflicting points 
of interaction between PB and stress would dysregulate macrophage-mediated 
inflammatory responses, which would provide feedback on the state of peripheral 
inflammation to the central nervous system via afferents of the vagus.  
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By inhibiting cholinesterases and thereby augmenting acetylcholine levels, PB would 
increase interactions between acetylcholine and cholinergic receptors across the 
parasympathetic nervous system, including via receptors on both macrophages and on 
the adrenal glands (H. Wang et al., 2003; S. P. Wilson & Kirshner, 1977). Cholinergic 
stimulation of chromaffin granules in the adrenal medulla results in the release of the 
catecholamines epinephrine and norepinephrine as part of the sympathetic nervous 
system, also colloquially termed the “fight or flight response.” Because stress also 
activates the sympathetic nervous system, it is possible that the noradrenergic response 
to stress would be augmented following PB. Norepinephrine activates α-adrenergic 
receptors on macrophages to stimulate NF-κB and consequently release a variety of 
cytokines including TNF-α, IL-6, and IL-1β (Bierhaus et al., 2003). However, increased 
acetylcholine would also interact with nicotinic α7 receptors on macrophages which 
would inhibit NF-κB and attenuate inflammation. Stress further complicates regulation 
of immune function as it also has a bimodal influence on inflammation, first increasing 
cytokines through noradrenergic signaling but also inhibiting NF-κB through 
glucocorticoid signaling in macrophages (Raison, Capuron, & Miller, 2006). Because of 
the complicated relationship between macrophages and the appropriate modulation of 
inflammation, PB may exacerbate the effects of stress and further disrupt homeostatic 
mechanisms modulating proper inflammatory responses. This hypothesis is supported 
by the fact that in response to an LPS challenge, IL-6 and TNF-α are attenuated in 
plasma of PB-treated rats relative to vehicle-treated rats, suggesting that PB impairs the 
ability of the immune system to mount an appropriate inflammatory response.  
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Dysregulation of inflammatory networks has important implications for neural 
function, as cytokines act directly on vagus afferents to provide neural feedback of the 
peripheral inflammatory state. In addition, cytokines can directly influence neural 
activity by either crossing the blood-brain barrier or stimulating glial cells by the blood-
brain barrier. As such, interactions between stress and cytokines may provide the first 
step towards cognitive dysfunction evidenced in veterans with GWI. This hypothesis is 
supported by clinical studies which consistently demonstrate that immune dysfunction 
is a hallmark feature of GWI (Broderick et al., 2011, 2013; Khaiboullina et al., 2015; 
Zhang et al., 1999).  
Modeling PB and Stress and the Cellular Mechanisms for Learning and Memory 
 In addition to interacting at multiple points in peripheral systems, stress and PB 
also produce many convergent and synergistic changes how the brain responds 
neurochemically to either an LPS (Figure 5.5) or restraint stress challenge (Figure 5.6). 
As these models demonstrate, some of the neurochemical changes in PB-stressed rats 
are driven independently by PB or stress whereas others are a result of synergistic 
effects between PB and stress. For example, while PB and stress both independently 
and in combination produce decreases in the cholinergic and glutamatergic response to 
a challenge (either LPS or restraint stress) in the PFC, glutamatergic systems in the 
hippocampus continue to respond as if they have no prior stress history. This failure in 
hippocampal glutamatergic systems to adapt to repeated stressors could have multiple 
causes and consequences. For example, decreases in cortical processing of stressful  
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Figure 5.5. Neurochemistry of LPS in a model of GWI. A. Cholinergic terminals project 
diffusely across the PFC to modulate the excitatory-inhibitory balance via muscarinic 
(mACh) and nicotinic (nACh) receptors. A history of stress decreases the cholinergic 
response to LPS in both vehicle and PB-treated rats. B. PB decreases glutamate in the 
PFC in response to LPS, irrespective of stress-history. This decrease in glutamate could be 
attributable to reductions in local signaling or afferents from distal brain regions, such as 
the Thalamus. C. Decreases in cholinergic and glutamatergic processing of new stressful 
stimuli could provide an underlying mechanism for impairments in PFC-driven cognitive 
function in veterans with GWI. D. Both PB and stress decrease the cholinergic response 
to LPS in the hippocampus. PB also decreases plasma levels of IL-6 and TNF-α. In the 
brain, IL-6 is regulates the temporal specificity of LTP; TNF-α regulates stability of 
synaptic plasticity my mediating AMPA trafficking. E. Combinations of PB and stress 
produce synergistic effects on the glutamatergic response to LPS in the hippocampus. F. 
Combined deficits in cholinergic, glutamatergic, and cytokine systems could impair the 
stability of LTP and thus decrease memory function. 
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Figure 5.6. Neurochemistry of Restraint Stress in a Model of GWI. A. A prior history of 
PB or restraint stress both independently and in combination decrease the cholinergic 
response to a stressful stimulus in the PFC. B. A history of stress decreases the 
glutamatergic response to stressful stimuli in the PFC. This decrease in glutamate could 
be attributable to reductions in local signaling or afferents from distal brain regions, 
such as the Thalamus. C. Decreases in cholinergic and glutamatergic processing of new 
stressful stimuli could provide an underlying mechanism for impairments in PFC-driven 
cognitive function in veterans with GWI. D. While both PB and stress decrease the 
cholinergic response to stressful stimuli in the hippocampus independently, 
combinations of PB with stress synergize to increase the cholinergic response to a 
restraint challenge. E. PB and stress also produce synergistic effects on the 
glutamatergic response to a stressful challenge. F. Failure in the cholinergic and 
glutamatergic systems’ adaptation to stress in the hippocampus could either be 
reflective of impaired hippocampal-dependent memory in veterans with GWI. 
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stimuli induced by PB and stress could impair the salience of the stressful event which 
would have downstream effects on memory-formation. 
In addition, if IL-6 and TNF-α are decreased in the hippocampus like they are in 
the plasma in response to LPS, then this would have important consequences for the 
appropriate assimilation of the cellular mechanisms for memory: LTP. IL-6 and TNF-α are 
constituently expressed under normal physiological conditions. IL-6 is associated with 
proper temporal tuning of LTP, exhibiting a negative regulatory feedback. TNF-α 
facilitates AMPA receptor trafficking, influencing the stability of newly formed synapses. 
Either too much or too little IL-6 or TNF-α produces deficits in synaptic plasticity and the 
stability of new memories. As such, deficits in cortical processing of stressful stimuli in 
addition to deficits in cytokine-mediation of synaptic plasticity could underlie some of 
the surprising neurochemical responses in the hippocampus to PB and stress. These 
shifts in the neurochemical response to a stressful challenge provide a potential 
mechanism underlying cognitive deficits in soldiers with GWI. 
Our studies provide insight as to how shifts in acetylcholine, glutamate, and 
cytokines may be influencing the cellular processes underlying learning and memory in a 
model of GWI. In addition, as deficits in contextual fear conditioning in PB-stressed rats 
appear transient, these acute shifts in cognitive processing of stressful stimuli may have 
important consequences for maintenance and progression of GWI as veterans returning 
from deployment face a host of stressors upon reintegrating into society. An inability of 
the central nervous system to adapt to repeated stressors may increase the sensitivity 
to neural damage from oxidative stress, thus exacerbating the effects of PB and stress. If 
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shifts in cognitive processing in response to recurrent stressors is a factor in 
perpetuating the progression of GWI, treatment strategies would need to emphasize 
two primary goals: 1) to stop the progression of GWI, and 2) to reverse physiological and 
cognitive deficits in GWI. 
 
5.4 FUTURE DIRECTIONS AND TREATMENT STRATEGIES 
The current experiments highlighted the importance for discerning interactions 
between stress and PB over time. As such, future microdialysis studies will need to 
determine if the effects of LPS and a restraint stress challenge shift at three-months 
post-treatment time point. In addition, while the current study examined changes in 
peripheral cytokines, future studies will need to determine if brain cytokine levels 
parallel those of plasma in this model of GWI. However, a priority of future studies 
should also be to examine potential treatment options. With veterans from the Gulf 
War continuing to age, the search for appropriate treatment strategies is becoming 
increasingly urgent. 
This hunt for appropriate treatment strategies is complicated due to the 
multifactorial nature of the illness, and it is possible that different treatments will be 
necessary to target different symptoms. There has been some success in identifying 
potential interventions which modestly improve cognitive symptoms of GWI. For 
example, one study found that twelve weeks of cognitive behavioral therapy in 
combination with mild aerobic exercise provided a mild improvement in cognitive 
function, although these improvements were transient and declined post-therapy 
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(Donta et al., 2003). Other symptoms such as chronic pain proved to be treatment-
resistant. Antioxidant treatment in Gulf War veterans yielded similar results with 
improvements in cognitive functioning but no improvements in other symptoms 
including fatigue or hyperalgesia (Baraniuk, El-Amin, Corey, Rayhan, & Timbol, 2013). 
As preclinical and clinical studies have routinely suggested alterations in immune 
function in veterans with GWI, directly targeting immune function may be a successful 
treatment strategy. Our studies support this hypothesis as PB produced robust effects 
on the innate immune system over time, demonstrating shifts in both basal cytokine 
levels and an impaired cytokine response to LPS. However, because of the unique 
conditions of the Gulf War, restoring proper balance in the immune response may be 
complicated. For example, cholinesterase inhibitors have been used as anti-
inflammatories in various disorders of neuroinflammation, but the chronic disruption of 
cholinesterase activity in PB-stressed rats suggests that use of a cholinesterase inhibitor 
may not be successful in these populations.  
Because of the combined deficits in both central and peripheral systems, 
targeting the vagus nerve may be an alternative strategy. The vagus nerve provides a 
link between the brain and the body, and stimulation of the vagus nerve produces a 
strong anti-inflammatory effect (Borovikova et al., 2000). Stimulation of the vagus nerve 
has been proposed as an effective treatment strategy for a variety of inflammatory 
disorders, including treatment-resistant depression (Rush et al., 2000; Sackeim et al., 
2001), and experimentally-induced pain (Kirchner, Birklein, Stefan, & Handwerker, 
2000). Because hyperalgesia is one of the more difficult symptoms to treat in GWI, vagal 
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stimulation could potentially provide a unified treatment for cognitive deficits as well as 
fatigue and hyperalgesia.  
Another potential treatment strategy for GWI would be to target the kynurenine 
pathway. Although kynurenic acid was originally considered an inert metabolite of 
tryptophan degradation in the kynurenine pathway, it is now associated with a wide 
range of physiological functions in both the central and peripheral nervous systems 
(Moroni, Cozzi, Sili, & Mannaioni, 2012). Centrally, kynurenic acid competitively 
antagonizes hippocampal glutamatergic NMDA (Perkins & Stone, 1985) and non-
competitively antagonizes cholinergic α7nACh receptors (Hilmas et al., 2001). In 
addition, kynurenic acid acts as an endogenous antioxidant in a mechanism that is 
independent from its glutamatergic or cholinergic interactions (Lugo-Huitrón et al., 
2011). Due to the widespread physiological effects of kynurenic acid in the brain, its 
unsurprising that kynurenic acid has been linked to a variety of disorders. For example, 
increasing kynurenic acid by inhibiting kynurenine 3-monooxygenase (KMO), an enzyme 
which regulates a divergent metabolic pathway, is neuroprotective in a mouse model 
for Alzheimer’s and Huntington’s disease (Zwilling et al., 2011). Peripherally, decreased 
production of kynurenic acid and overproduction of 3-hydroxykynurenine by KMO is 
positively associated with IL-6 and TNFα, oxidative stress, and cardiovascular disease (Q. 
Wang, Liu, Song, & Zou, 2016), all of which have been implicated in GWI. Therefore, 
increasing kynurenic acid by antagonizing KMO could provide a novel and unified 
treatment strategy for GWI that targets both peripheral and central symptoms.  
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5.5 CONCLUSIONS 
 The current studies provide insight into neurochemical, behavioral, and 
physiological effects of chronic PB treatment and stress. Although the primary 
hypotheses was that PB and stress interact to cause deficits in GWI, our study found 
that some effects were primarily driven by PB, some by stress, and others by synergistic 
combinations of PB and stress. The current studies also provided insight towards the 
controversial debate of whether PB can impact the central nervous system. Although 
these studies did not assess whether PB crossed the blood-brain barrier, they did 
demonstrate that PB impacts central cholinergic function regardless of this fact.  
The effect of PB on central cognitive function is complex, varying by both 
stimulus and brain region. Importantly, since PB did not impact basal levels of 
acetylcholine, this suggests that the effects of PB are stimulus-dependent. In general, 
while these effects of PB on acetylcholine were not synergistic with stress, PB and stress 
did produce synergistic effects on glutamatergic function with the hippocampus being 
particularly sensitive to these interactions. This would suggest that in GWI, 
glutamatergic systems – particularly hippocampal glutamatergic systems – may be a 
prime target for intervention and treatment strategies in veterans with GWI. 
Currently, GWI remains treatment-resistant with symptoms continuing to become 
exacerbated with time. Our study highlights that PB and stress interact to produce 
unique changes in the brain’s neurochemistry, thus potentially providing a mechanism 
underlying cognitive dysfunction in veterans with GWI. Understanding the 
neurochemical deficits in Gulf War Illness is an important precursor to providing 
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effective treatment strategies for this treatment-resistant population. This treatment-
centered objective is urgent as veterans from the Gulf War continue to age. Thus, 
finding successful treatment strategies to either halt or reverse the progression of GWI 
is paramount in a race-against time. Moreover, as PB remains approved as a nerve-
agent pretreatment drug, these studies highlight the importance of using this drug 
cautiously in soldiers as it produces several long-term detrimental changes to vertebrate 
physiology 
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